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The immunosuppressive activity of Mesenchymal Stromal Cells (MSCs) is 
well documented, but the therapeutic benefit is completely unpredictable. 
Prospective randomized clinical trials remain the only means to address MSC 
clinical efficacy. However, their success is undermined by the difficulty to 
stratify patients. Probably the most challenging conundrum is that, despite 
being immunosuppressive, MSCs are undetectable following administration. 
Therefore, understanding the fate of infused MSCs could help to shed light 
on the mechanisms of MSC immunobiology and predict clinical responses. 
 
We decided to focus our attention on MSCs used for the treatment of Graft 
versus Host Disease (GvHD), since there is proof-of-principle of their efficacy. 
In order to address the mechanisms used by MSCs to deliver 
immunosuppression we adopted a preclinical model of GvHD by which we 
demonstrated that MSCs are actively induced to undergo perforin-dependent 
apoptosis by recipient cytotoxic cells and that this process is essential to 
initiate MSC-induced immunosuppression. When examining patients with 
GvHD who received MSCs we found a striking parallel, whereby only those 
with high cytotoxic activity against MSCs responded to MSC infusion whereas 
those with low activity did not. Importantly, the need for recipient cytotoxic cell 
activity could be replaced by the infusion of apoptotic MSCs generated ex 
vivo. After infusion, recipient phagocytes engulfed apoptotic MSCs and 




These results point out that crucial events for the delivery of MSC 
immunosuppressive activity take place soon after infusion. This observation 
was also supported by the retrospective analysis of the clinical data of a 
cohort of 60 steroid-resistant acute GvHD patients treated with MSCs, since 
the assessment of the response as early as 1 week after MSC administration 
is sufficient for predicting the survival of the patients. 
 
In summary, we propose the innovative concept that response should be 
assessed early after starting MSC treatments, and patients should be 
stratified for MSC treatment according to their ability to kill MSCs. Our results 
strongly suggest the intriguing possibility to treat patients with immune 
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1 General Introduction 
 
1.1 The mesenchymal stromal cells dilemma: one, hundreds 
or thousands of entities? 
 
Mesenchymal Stromal Cells (MSCs) consist of a highly heterogeneous 
population of stem and progenitor cells selected and expanded in vitro as 
unfractionated fibroblastic-like and plastic-adherent cells1. A precise definition 
of these cells yet remains predominantly ambiguous, despite the surge of 
references in the literature and the escalation of the number of clinical trials 
using these cells during the last decades2. The MSC acronym itself, widely 
employed and acknowledged from the scientific community, has been 
challenged in relation to its real connotation. 
 
First isolated in mouse bone marrow in the late sixties, as non-
haematopoietic, adherent cells able to give rise to colonies of fibroblastic-
shaped cells (thus defined as colony-forming units–fibroblastic)3, these cells 
were then termed “marrow stromal stem cells” by Owen twenty years later4, 
based on their origin (marrow), their property of self-renewal and to 
differentiate (stem) in vitro into a spectrum of fully differentiated cells of the 
connective tissue (stromal)5. In a provocative attempt to challenge the widely 
accepted idea that the only stem cells in mammalian organisms were 
haematopoietic stem cells (HSCs), Caplan coined the term “mesenchymal 
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stem cells” to further reinforce the notion of stemness of these cells which 
were for the first time referred to as “MSCs”6. However, the capacity of MSCs 
to differentiate into different lineages was initially confined to in vitro 
experiments7, thus making the actual relevance of the stemness property 
equivocal. It was then proposed to use the more conservative expression, 
multipotent mesenchymal stromal cells8, and minimal criteria for defining 
MSCs9 were introduced. Based on these criteria, MSCs were defined by the 
positivity of few non-specific markers (CD105, CD73 and CD90) and 
negativity of others (CD14 or CD11b, CD19, CD31, CD34, CD45, CD79a), 
combined with the capacity to produce polyanionic, hydrophobic and 
mineralized products under specific and artificial in vitro conditions9. Cells 
meeting these criteria could be obtainable from any (virtual all) stromal 
tissues10–15 and could be extremely variable in regards to differentiation 
stage, proliferation rates, functional characteristics and morphology, as 
already demonstrated by early investigations4,7,16,17. Although new sets of 
markers have been recently proposed, the characterization of MSCs yet 
remains elusive18. Main obstacles to a better clarification originate by the 
extreme difficulty in understanding whether MSC heterogeneity originates 
from the different culture manipulations or reflects the innate heterogeneity of 
the in vivo repertoire of MSC subsets19. To this regard, many investigations 
have been performed to try to identify the cell/s of MSC origin in the body. 
Since its very first isolation, MSCs were hypothesized as part of a wide 
stromal cell system of the body4. It has now become apparent that most MSCs 
derive from specific progenitors located mainly in the perivascular space20, 
thus posing the question of the identity between MSCs and pericytes21. 
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However, this concept has been challenged by the observation that MSCs 
are not located exclusively around vessels22 and not always MSCs and 
pericytes share the same markers23. 
 
Despite their wide heterogeneity, MSCs have been used as cellular 
therapeutic tools in many diseases. The successes of early studies, whereby 
MSCs were used to sustain engraftment after Haematopoietic Stem Cell 
Transplantation (HSCT)24, or to ameliorate disparate diseases such as 
Osteogenesis Imperfecta25 or Graft versus Host Disease (GvHD)26, greatly 
contributed to the confidence on MSC potentials. Clear evidence of this 
climate is the incredible fast-paced increase of studies whereby MSCs were 
used for the treatment of diseases affecting multiple sites27–31. 
 
Two main MSC features underpin the therapeutic potentials of MSCs: 
regenerative and immunosuppressive properties. They are not mutually 
exclusive or completely independent as tissue regeneration requires 
resolution of injury-associated inflammation. 
The multipotency of MSCs will not be further discussed (reviewed in 32 and 
20). Conversely, their immunosuppressive properties will be extensively 







1.2 Immunomodulating properties of MSCs 
 
1.2.1 General concepts in MSC immunobiology. 
 
Among MSC functions not related to stemness or multipotentiality, the most 
intriguing is their immunomodulatory activity. There is extensive evidence that 
MSCs exert potent immunosuppressive effects in vitro against virtually any 
cell of both the innate and adaptive immune system (Figure 1.1). Despite the 
degree of MSC heterogeneity described above, this property seems to be 
shared with many (if  not all) stromal cells from different tissues33–37. However, 
since Bone Marrow (BM) derived MSCs were the first to be isolated and 
tested in patients, they still remain the most commonly used MSCs in clinical 
studies and represent the term of comparison for MSCs obtained from other 
tissues. 
 
CD4+ and CD8+ T cells are both significantly inhibited by MSCs in a non-
specific and non-selective way, regardless of their previous encounter with 
their cognate antigen38, activation state or type of T-cell receptor (TCR) 
expressed39. Both allogeneic and autologous MSCs can exert 
immunosuppression, thus suggesting that immunomodulation is not mediated 
through major histocompatibility complex (MHC) restriction40,41. In the 
presence of MSCs, T-cell proliferation is reversibly inhibited41 and their cell 
cycle is arrested in the G0/G1 phase through inhibition of cyclin D2 and up-
regulation of p27Kip1 expression42. This effect does not seem to interfere with 
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T cell activation processes, since the expression of CD69, CD25, and 
cytotoxic T-lymphocyte–associated antigen-4 (CTLA‐4) on T cells is similar in 
the presence or absence of MSCs43. Despite this very potent MSC anti-
proliferative activity, also contrasting results have been reported. Indeed, 
while at lower Peripheral Blood Mononuclear Cells (PBMC)/MSC ratios MSCs 
exerted potent anti-proliferative activity against PBMCs, at higher ratios this 
property was reverted and PBMC proliferation indeed stimulated44. Similarly, 
the addition of poly(I:C) (Toll-like receptor 3 [TLR3] ligand) and 
Lipopolysaccharides (TLR4 ligand) to the T cell/MSC co-culture almost 
completely abrogated MSC anti-proliferative activity45. Taken together, these 
observations seem to suggest that the MSC suppressive activity is dependent 
on culture conditions and their ratio with T cells. 
 
As for T cells, MSC effects on Natural Killer (NK) cells seem to be complex 
and strictly dependent on the balance between environmental cues and 
activation state of NK cells. It has been demonstrated that MSCs could inhibit 
freshly isolated or resting NK cell proliferation upon stimulation with 
interleukin-2 (IL-2) alone46, IL-2 in combination with T-cell depleted allogeneic 
PBMCs43, or IL-1547. This inhibition was associated with significant reduction 
in NK production of the inflammatory cytokines Interferon-γ (IFN-γ) and 
Tumour Necrosis Factor-α (TNF-α), and in NK cytotoxic activity against their 
targets43,47. Conversely, NK cell proliferation is only minimally affected by the 
presence of MSCs when NK cells are pre-activated with IL-246. In this setting, 
both autologous and allogeneic MSCs were lysed by activated NK cells and 
the cytotoxic activity seems to be mediated by the MSC expression of the 
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proteins UL16 binding protein, poliovirus receptor (CD155) and Nectin-2, 
ligands of the NK activating molecules natural killer group two C and DNAX 
Accessory Molecule-1, respectively46. Similar results were obtained when NK 
cells were pre-activated with IL-1547. Notably, when MSCs were pre-treated 
with IFN-γ before the co-culture with IL-2 activated NK cells, their 
susceptibility to lysis was completely reverted as a result of up-regulation of 
Human Leucocyte Antigen (HLA) type I on MSC surface46. 
 
MSCs exert their immunomodulatory effects also against B cells. Several 
studies using murine in vitro models demonstrated the anti-proliferative 
activity of MSCs when in co-culture with B cells42, with decrease in the IgG 
secretion and expression of the activation marker CD2548 through the 
involvement of the Programmed Death-1 (PD-1) pathway49. Similar findings 
were obtained using co-culture of human B cells and MSCs. In this system, 
B cells were arrested in the G0/G1 phase of the cell cycle as T cells, while 
their viability was preserved50. Furthermore, the production of IgM, IgG, and 
IgA was inhibited and chemotaxis through C-X-C chemokine receptor-4 
(CXCR4) and CXCR5 axes impaired50. Nevertheless, these results were in 
contrast with other reports whereby MSCs had no effect on B cell 
proliferation43, or conversely had a stimulatory effect on B cell proliferation 
and secretory activity51. As observed for T and NK cells, also the MSC 





Taken together, these observations underpin one of the most important 
features of MSC immunobiology: its functional plasticity. MSC inhibitory 
activity is not constitutive, but it needs to be elicited by the inflammatory 
microenvironment through a mechanism commonly defined as “licensing”1. 
Cytokines mainly involved in this process are IFN-γ43,52, IL-1β and TNF-α53. 
Nonetheless, the licensing effect on MSCs could change, depending on the 
specific inflammatory stimuli. Indeed, it has been observed that specific 
concentration of IFN-γ could turn MSCs into potent Antigen Presenting Cells 
(APCs)54–56, while the presence of TLR3 and TLR4 ligands could impair the 
MSC immunosuppressive properties and restore an effective T cell 
response57. 
 
As described in this paragraph, MSCs exert a broad arsenal of 
immunosuppressive capabilities which place them as important coordinator 
of the immune system. This multifactorial role cannot be executed only by a 
direct activity on the ultimate immune effector cells but it requires also 
additional contact-dependent and -independent signals with other regulatory 
cells1,33,58. It has been proposed that it is through either a direct and an indirect 
activity that MSCs can create a network of cellular interactions and 
communication which eventually define the impact of MSCs on inflammatory 
responses. In the next two paragraphs, these two not mutually exclusive 
mechanisms will be discussed.
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Figure 1.1. Summary of the immunosuppressive mechanisms employed by MSCs described in vitro. In the presence of an 
inflammatory environment, MSCs are “licensed” to produce different molecules which can mediate a very potent immunosuppressive 
activity against any cell of the immune system. Blunt line: inhibition. Arrowed line: stimulation. CCR7: C-C receptor-7. CXCR4: C-X-
C chemokine receptor type 4. CXCR5: C-X-C chemokine receptor type 5. HLA: human leukocyte antigen. HO-1: heme oxygenase-
1. IDO: Indoleamine 2,3-dioxygenase. IFNγ: Interferon. IgA: Immunoglobulin A, IgG: Immunoglobulin G, IgM: Immunoglobulin M. IL-
1β: Interleukin-1β. IL-6: Interleukin-6. IL-10: Interleukin. IL-12: Interleukin -12. iTreg: induced Regulatory T cells. MHC: major 
histocompatibility complex. nTreg: natural Regulatory T cells. PGE2: Prostaglandin E2. PDL-1: Programmed death-ligand 1. TSG-6: 
Tumour necrosis factor-inducible gene 6. TGF-β: Transforming growth factor-β
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1.2.2 MSC immunosuppression by direct activity  
 
The secretion of soluble factors plays a fundamental role in MSC 
immunosuppression 33, and several factors have been described. 
 
1.2.2.1  Indoleamine 2-3 dioxygenase 1 (IDO1) 
 
IDO1 represents the best characterized enzyme in MSCs of human orgin59. 
IDO-1 is one of the rate-limiting enzymes regulating the kynurenine pathway. 
By controlling the oxidative cleavage of the indole ring of Tryptophan into N’-
formylkynurenine, it controls the catabolism of tryptophan and its metabolites 
kynurenines60. IDO expression is tightly regulated and dependent on the 
presence of T helper type 1 (Th1) inflammatory cytokines (IFN-γ being the 
most potent inducer) in the microenvironment61–63, or on the interaction of 
CTLA-4 and CpG oligonucleotides with B7 molecules64–66 and TLR967, 
respectively. The activation of the kynurenine pathway plays a key function in 
both the innate and the adaptive immune systems by directly controlling 
pathogen replication in several chronic infections68–71, and limiting 
indiscriminate damage in inflamed sites during microbial invasion72. However, 
the discovery that IDO could serve as immunosuppressive factor to protect 
foetal allografts from immunological rejection73 sparked interest in 
investigating IDO in immune tolerance. IDO central role in the induction of 
tolerance to self-antigens has been comprehensively confirmed in several in 
vivo studies of allograft rejection, and autoimmune diseases (reviewed in 61). 
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IDO is also important in the generation of peripheral tolerance to neoantigens 
expressed in tumour tissues74. Indeed, the use of the IDO inhibitor 1-
Methyltryptophan (1-MT) was able to reverse this immunosuppression and 
could complement the therapeutic activity of antineoplastic drugs in 
eradicating experimental models of cancer. The synergistic activity of 1-MT 
was immune mediated, since it was lost in mice deficient of a T cell 
response75. The biochemical pathways employed by IDO to modulate 
immune responses are still object of investigations. What is emerging is a 
complex scenario whereby both tryptophan depletion and accumulation of 
kynurenines might play dual and not mutually exclusive roles in the 
generation of immunosuppressive effects. Tryptophan depletion leads to a 
direct suppression of T cell activation and proliferation secondary to amino 
acid starvation which activates the amino acid sensitive general-control-non-
repressible 2 stress kinase pathway and blockage of the mammalian target 
of rapamycin signalling61. Increase of kynurenines in the microenvironment 
mediates the acquisition of a tolerogenic phenotype in APCs dependent on 
the downregulation of the expression of MHC class II and the co-stimulatory 
molecules CD80, CD86 and CD4076. Furthermore, there have been reports 
demonstrating that T cells are sensitive to the antiproliferative and cytotoxic 
activity of tryptophan metabolites themselves both in vitro77 and in vivo78, and 
that some of the kynurenines produced after tryptophan degradation could 
prolong skin allograft survival in rats79. It has been demonstrated that the 
generation of regulatory T cells (Treg) can be elicited by both 
mechanisms80,81. It is then plausible that more than one mechanism might be 
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employed by IDO in its tolerogenic activity, the relevant importance thereof 
varying with the specific system considered. 
 
The production of IDO by MSCs and its role in mediation of MSC 
immunosuppression has been extensively described43,59,82–85. IDO is not 
constitutively expressed in MSCs, but its production is induced by the 
presence of IFN-γ in the microenvironment43,59,82,84. As described in the first 
part of the paragraph, also in the case of the IDO produced by MSCs, the 
immunosuppression can be mediated by tryptophan starvation and/or 
kynurenine accumulation, the importance of which varies depending on the 
specific setting considered59,84. IDO induction is also associated with the 
ability of MSCs to interact and orchestrate the immunosuppressive activity of 
other cells of the immune system such as Treg cells85 and macrophages83. 
This important interaction will be thoroughly analysed in the paragraph 
entitled “MSC immunosuppression by indirect activity on regulatory cells. 
 
1.2.2.2 Prostaglandin E2 (PGE2) 
 
PGE2 is the most abundant eicosanoid lipid mediator in the human body and 
exerts a wide range of activities regulating several physio-pathological 
processes at disparate sites86–88. The synthesis of PGE2 comprises the 
release of the precursor arachidonic acid from the plasma membrane by 
phospholipase A289, the production of PGG2 and PGH2 by the activity of the 
rate-limiting enzyme Cyclooxygenase (COX), and the final conversion into 
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PGE2 by three specific synthases90,91. Two isoforms of COX have been 
identified: while COX1 is constitutively expressed in any tissues and mainly 
regulates homeostatic processes92, COX2 can be induced by many pro-
inflammatory or mitogenic stimuli (such as IL-1β, TNF-α or lipopolysaccharide 
[LPS])93 and seems to account for most of the prostanoids produced during 
inflammation. However, this concept has been challenged by observations 
that also COX1 could be induced and take part into inflammatory responses 
in human cells in vitro 94,95 and in mouse systems in vivo96. 
 
PGE2 exerts its activity through ligation with four different G-protein-coupled 
receptors nominated as EP receptors (EP1 to EP4). Upon ligand binding, EPs 
specifically mediate different intracellular pathways triggering changes in the 
production of intracellular cyclic adenosine monophosphate, or in Ca2+ 
mobilization97. PGE2 is traditionally considered one of the most important 
mediators of the four cardinal signs of inflammation (rubor [redness], calor 
[heat], tumor [oedema and swelling], and dolor [pain]) 97, however its role in 
hampering T cell proliferation was described over 40 years ago98. 
 
The inhibition of T cell proliferation and activation is mediated by an 
interference with the IL-2/IL-2R axis99,100 and/or with the antigen-induced TCR 
activation101,102. Furthermore, PGE2 is able to induce the expression of the 
transcription factor forkhead box P3 (FOXP3) in human CD4+CD25- cells to 
acquire regulatory functions103,104. As a consequence, T cells are skewed 
towards a Th2 phenotypes with reduced levels of IL-2 and IFNγ, and 
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increased IL-4 and IL-5 production105. Accordingly, PGE2 induces the 
production of IgG1 and IgE in B cells stimulated with IL-4 and LPS106. 
However, the regulation on B cell activity seems to depend on the maturation 
stage. Indeed, while enhancing the proliferation of mature B cells, PGE2 
exerts anti-proliferative activity on immature B cells107. 
 
However, the role of PGE2 in immunomodulation is far more complex than 
previously thought. For example, while PGE2 stimulates DCs activation in 
peripheral tissues, it exhibits opposite effects after Dendritic Cells (DCs) have 
migrated to the lymph nodes, whereby DC maturation and antigen-presenting 
capacity is inhibited93. Furthermore, PGE2-licensed DCs induce naive T cells 
to differentiate into Th2 cells108. Conversely, if DCs are treated with PGE2 in 
the presence of LPS, they secrete large amounts of IL-23, thereby facilitating 
the differentiation of pro-inflammatory Th17 cells109. This pro-inflammatory 
activity is further supported by the observation that PGE2 can also directly 
promote Th1 and Th17 differentiation and expansion after TCR triggering110 
by engaging EP2 and EP4 receptors, thus playing an important role in the 
pathogenesis of experimental autoimmune encephalomyelitis, and in a model 
of contact hypersensitivity111. The role of PGE2 in regulating immune 
responses is extremely complex and the net result of PGE2 activity depends 
on the specific PGE2 receptors expressed on the immune cells, their 
maturation state, PGE2 concentrations, the concomitant presence of other 




PGE2 is constitutively expressed in MSCs and its production is significantly 
induced after culture of MSCs with activated PBMCs or recombinant TNFα, 
IFNγ40,84,112. It has been demonstrated that PGE2 concentrations in 
MSC/PBMC co-cultures were associated with the anti-proliferative activity of 
MSCs112,113. Inhibition of PGE2 synthesis by the use of the COX2 inhibitors 
indomethacin or NS398 significantly abrogated the anti-proliferative activity 
of MSCs against both mitogen induced or antigen-specific T-cell 
proliferation40,84,114. Furthermore, genetically ablation of COX2 in MSCs 
completely abrogate the capacity of MSCs to ameliorate neuroinflammation 
in a pre-clinical model of traumatic brain injury113. The production of PGE2 in 
MSCs has also been associated with the capacity of MSCs to induce 
macrophage polarization toward an M2 profile115,116, to shift the polarization 
of T cells toward a Th2-type differentiation with inhibition of IFNγ and 
stimulation of IL-4 production40, and to reduce TNFα production while 
increasing IL-10 secretion in LPS-stimulated DCs40. 
 
1.2.2.3 Tumour necrosis factor-stimulated gene 6 (TSG-6) 
 
TSG-6 is a 35 kDa glycoprotein117 which can be secreted in human 
fibroblasts, synoviocytes, chondrocytes, vascular smooth muscle cells or 
proximal tubular epithelial cells after induction by several stimuli including 
TNFα and IL-1, depending on the cell type considered117–121. Also PBMCs are 
able to produce TSG-6 in the presence of inflammation and LPS117,118. TSG-
6 could exert an anti-inflammatory activity, as demonstrated in several in vivo 
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models of acute inflammation or antigen-induced arthritis122–125. Despite the 
variety of potential mechanisms employed by TSG-6 to deliver its anti-
inflammatory activity122,126–128, the specific pattern yet remains poorly 
elucidated. It is important to highlight that the effect seems to be mainly 
directed against the innate immunity and the acute phase of inflammation with 
a specific activity against neutrophil influx122–124,126,129, without hampering the 
antigen-specific T-cell response125,129,130. However, an activity on the 
adaptive immune system cannot be completely ruled out, since a reduction 
of disease-specific antibodies in the serum of experimental animals with 
collagen-induced arthritis was also observed in the presence of TSG-6124,129. 
 
MSCs constitutively express TSG-6 at very low levels and this production is 
significantly increased in the presence of inflammatory cytokines such as 
TNFα131–133 or bone morphogenetic protein 2134. TSG-6 production by MSCs 
was able to polarize macrophages toward an M2 phenotype133, with inhibition 
of the secretion of TNFα in vitro132,134 which was dependent on the reduction 
of the translocation of nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) in macrophages mediated by the interaction between TSG-6 
and CD44. The secretion of TSG-6 seems to be part of the 
immunosuppressive armamentarium of MSCs, at least in models where acute 
inflammation plays a central role. Indeed, it has been reported that MSCs 
were able to significantly attenuate the inflammatory infiltration in a mouse 
model of peritonitis or inflammatory bowel disease (IBD), and this property 
was completely abrogated when TSG-6 expression was genetically silenced 
in MSCs by the use of specific small interfering Ribonucleic acid (RNA)132,133. 
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Notably, MSCs are induced to secrete large amount of TSG-6 after 
aggregation in microspheres upon activation of the Caspase1/NF-κB/IL-1 
inflammasome signalling pathway135,136. This observation has important 
implications on understanding the complex mechanisms employed by MSCs 
to deliver immunosuppression after infusion, since MSC aggregation and 
TSG-6 production spontaneously occur in vivo136, upon the formation of 
micro-emboli in the pulmonary vasculature after MSC intravenously 
injection131. Remarkably, MSCs trapped in lungs and activated to secret TSG-
6 were able to reduce the infiltration of neutrophils in the myocardium and 
plasmin activity in the serum in a preclinical model of myocardial infarct131. 
This activity, which translated in significant reduction of infarct size and 
improvement of heart function, was completely abrogated when TSG-6 was 
silenced in the transplanted MSCs. 
 
1.2.2.4 Transforming Growth Factor-β (TGF-β) 
 
TGF-β is a pleiotropic factor consisting of three different isoforms (TGF-β1-3) 
with effects on different biological processes including immunological 
responses137. In the canonical TGF-β signalling, ligation of TGF-β to type II 
serine/threonine kinase receptor initiates a cascade of signals leading to 
activation of three cytoplasmic Smad proteins (Smad 2, 3 and 4) 138. 
Alternatively, non-canonical TGF-β signalling cascades seem to mediate 
cancer progression when the canonical pathway is disrupted139. Since the 
first observation that TGF-β could inhibit IL-2 stimulated expansion of T 
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lymphocytes140, strong evidence proved the pivotal role of this cytokine in the 
regulation of the immune system. 
 
T cell proliferation of naïve T cells is strongly inhibited by TGF-β, mainly 
through blockage of IL-2 production140. Nevertheless, since very high doses 
of IL-2 to T cell culture only partially abrogated the anti-proliferative activity of 
TGF-β140, also other pathways, involving the cyclin-dependent kinase 
inhibitors p21 and p27, have been described141. Activated T cells are 
minimally sensitive to the antiproliferative activity of TGF-β which is however 
restored in the concomitant presence of IL-10142. 
TGF-β is able to hamper the differentiation of CD4+ T cells toward both a 
Th1143 or Th2144 phenotype, and can affect the ability of CD8+ T cells to 
mature into functional cytotoxic cells by inhibition of perforin145 and FAS 
ligand146 expression. This activity on T cell differentiation was confirmed in 
vivo by the observation that mice bearing TGF-β1 Receptor II-/- T cells 
developed a systemic autoimmune disease associated with an increased 
number of fully differentiated Th1 and Th2 T cells and spontaneously 
activated CD8+ T cells able to produce effector cytokines147. 
 
TGF-β also plays an important role in the regulation of Treg cells. It has been 
shown that TGF-β1 can induce in vitro Treg conversion from naïve T cells via 
induction and maintenance of Foxp3 expression148,149. Furthermore, TGF-β 
seems to be important in the maintenance of natural Treg cells (nTreg), since 
TGF-β-/- mice present reduced number of peripheral Treg cells150. This activity 
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seems to be dependent by a stabilization of Foxp3 expression in Treg cells 
mediated by the canonical TGF-β signalling pathway151. 
 
Although being mainly a suppressor factor on T cell functions, TGF-β has also 
an important role in the initiation of differentiation and Th17 cells152 which 
secrete an array of cytokines involved in inflammation and 
autoimmunity153,154. 
 
As already mentioned, TGF-β has pleiotropic effects which influence not only 
T cells but also other components of the immune system, thus greatly 
extending the relevance of this cytokine in the fine tuning of immunological 
responses. Some of these effects will be summarized in the next part of the 
paragraph. 
NK cells are strongly inhibited by TGF-β via attenuation of their IFNγ 
production and cytolytic activity155,156. 
 
The presence of TGF-β during DC maturation leads to accumulation of DCs 
with reduced antigen-presenting functions due to the retention of an immature 
phenotype characterized by low levels of CD1c and co-stimulatory molecules 
CD80 and CD86157,158. 
 
As for T and DCs cells, the activity of TGF-β on macrophages depends on 
their maturation state. Generally, during the acute phase of inflammation 
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TGF-β acts as a recruiting factor for monocytes159,160 via induction of 
adhesion molecules on monocytes and facilitation of monocyte 
transmigration to the site of injury161, whereby they are activated to produce 
inflammatory cytokines159,162. As the inflammatory response mounts and 
monocyte/macrophages mature, TGF-β suppressive activity starts to prevail. 
This inhibition affects macrophages at several levels of their activities such 
as phagocytosis163–165, LPS-induced cytokine secretion166, reactive oxygen167 
and nitrogen168 species production, and antigen presenting functions169,170. 
 
The complexity of the activities mediated by TGF-β is further increased by the 
fact that most of the cells susceptible of its effects can secrete it in the 
microenvironment. Furthermore, also non-classical immunologic cells can 
produce these cytokines. 
 
MSCs constitutively produce TGF-β in specific culture conditions171 and its 
secretion has been described as an important mechanism employed by 
MSCs to mediate immunomodulatory effects. As already mentioned in the 
paragraph of the MSC immunobiology, MSCs exert potent anti-proliferative 
activity against T cells in vitro. This activity is mainly mediated by soluble 
factors41, however it has been shown this inhibition to be significantly stronger 
in the presence of MSCs/T cell contact172. Notably, TGF-β plays an important 
role in both mechanisms. Indeed, T cell proliferation is partially restored in a 
transwell system in the presence of blocking antibodies against TGF-β141, but 
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also seems to be responsible of the additive anti-proliferative activity 
observed when MSCs and T cells are in contact172. 
As for other soluble factors employed by MSCs, also TGF-β is implicated in 
the MSC activity of re-shaping the microenvironment into an 
immunosuppressive niche via interaction with other cells of immunological 
significance. In a mouse model of ovalbumin (OVA)-induced Th2-type lung 
inflammation, MSCs were able to reduce the principal hallmarks of the 
disease (airway hyperresponsiveness and eosinophilic accumulation in 
bronchoalveolar lavage [BAL]). This effect was dependent on the polarization 
of alveolar macrophages toward an M2 phenotype which was mediated by 
the production of TGF-β by MSCs173. Moreover, several studies have 
described the role of the TGF-β secreted by MSCs in the induction and 
expansion of Treg cells174–176. 
 
1.2.2.5 Role of other immunomodulatory factors 
 
In association to the factors described above, other molecules have been 
described as mediators of direct MSC immunosuppressive activity. 
 
Heme oxygenase-1 (HO-1) is the rate-limiting enzyme controlling the 
degradation of heme into biliverdin, free iron and carbon monoxide. HO-1 can 
exert potent anti-inflammatory effects by inhibiting the production of TNFα, IL-
1β, and macrophage inflammatory protein-1β while inducing secretion of IL-
10 in LPS-stimulated macrophages both in vitro and in vivo through the 
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mitogen-activated protein kinase pathway177. Furthermore, HO-1 hampers 
DCs maturation and their capacity to stimulate T cell proliferation in response 
to alloantigens178, and its overexpression in rats receiving heart transplant 
leads to long-term allograft survival179. Importantly, HO-1 has been 
demonstrated to exert pro-tumour effects, by inhibiting CD8+ cell responses 
against cancer cells180, thus its inhibition is now considered an important 
target of cancer immune check points181. HO-1 plays an important role in 
MSC mediated immunosuppression, as demonstrated by the observation that 
its inhibition could restore proliferation of human PBMCs when stimulated in 
Mixed Lymphocyte Reactions (MLR) in the presence of MSCs182. 
 
MSCs can secrete the soluble isoform 5 of the non-classic HLA class I 
molecule HLA-G (HLA-G5). HLA-G plays an important role in the 
maintenance of the maternal tolerance toward the foetus183, and its 
expression after solid organ transplantations is fundamental in the 
acceptance of the graft184,185. It has been demonstrated that HLA-G can have 
several immunosuppressive activities, including hampering the cytotoxic 
activity of CD8+ cells or NK cells186, or impairment of DC maturation187. MSC 
production of HLA-G5 requires IL-10 and cell-contact between MSCs and 
activated T cells, and it inhibits T cell proliferation and impairs NK cells 




Other molecules with immune suppressive activities described as produced 
by MSCs are galectin 1189, 3190 and 9191, and they could play a role in reducing 
both acute and chronic inflammatory responses. 
 
The direct suppressive activity of MSCs is not limited to the secretion of 
soluble factors. Indeed, MSCs can express ligands on their surface which 
interact with their counterpart on the membrane of immune cells, thus directly 
transmitting inhibitory signals. Examples of such mechanisms are the 
expression of programmed death-ligand 1 (PD-L1/B7-H1/CD274) and the 
membrane-bound HLA-G1. The expression of the former can be induced by 
IFNγ in MSCs and the interaction between PD-L1 with its receptor PD1 on T 
cells mediates inhibition of both proliferation and effector functions of 
activated T cells85. The latter is expressed by both BM-MSCs and MSCs 
obtained by foetal liver and can induce arrest of the cell cycle in T cells and 
inhibit their IFNγ production192. 
 
1.2.2.6 Interplay between factors 
 
In the previous paragraphs different molecular patterns have been 
extensively described. An important aspect to underline is that all these 
factors are part of a well-known system of the “innate tolerance” which can 
play an important role in different conditions, ranging from autoimmunity to 
cancer immune escape. The fact that most of them are employed by MSCs, 
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makes it conceivable that MSCs are important components of this tolerogenic 
systems. 
 
It is unlikely that any of these factors alone may represent the necessary and 
sufficient candidate accounting for the whole immunomodulating activity 
mediated by MSCs, especially in complex scenarios like in vivo settings. It is 
more likely that each factor concurs synergistically to the final production of 
an immunosuppressive niche. Same conditions can also activate different 
patterns, thus highlighting the remarkable complexity and redundancy of the 
molecular pathways activated in MSCs. Same stimuli can elicit different 
factors. For example, TNFα and IFNγ can induce IDO61–63, PGE240,84,112, 
TSG-6131–133. Similarly, formation of MSC micro-spheres can act as driver for 
the induction of both PGE2 and TSG-6116,136. Furthermore, IDO, PGE2, TSG-
6 and TGF-β exert specific activities on third cells (macrophages and Treg 
cells for instance) which in turn can produce any of these factors. It is then 
conceivable that the respective importance of these molecular patterns may 
have different levels of relevance, depending on the specific scenario or 
inflammatory context where MSCs are used. 
 
1.2.3 MSC immunosuppression by indirect activity on 
regulatory cells 
 
As emerged from the previous paragraph, MSCs can produce a wide range 
of factors which not only have direct immunomodulating effects but can also 
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play a role in the interaction between MSCs and other immune cells such as 
macrophages, DCs and Treg cells through a mechanism which can be 
defined as the “indirect immunosuppressive” activity of MSCs. The education 
of these cells orchestrated by MSCs will gather a network of regulatory 
immune cells which will support and maintain for longer terms the 
immunosuppressive niche created by MSCs through soluble factors. 
 
1.2.3.1 Expansion of T cells with regulatory properties 
 
The concept of a subpopulation of T-cells with regulatory properties was first 
presented in the 1970s193. Since then, the pivotal role played by these cells 
in immune homeostasis and maintenance of self-tolerance has been 
extensively confirmed both in mice and humans; and the term Treg cells was 
then introduced194,195. Initially, Treg cells were thought to be a distinct 
subpopulation within CD4+ T cells specifically expressing both the IL-2 
receptor α-chain CD25+196,197 and FOXP3198–200 in opposition to conventional 
effector CD4+ T cells. However, it is now clear that the expression of both 
markers is not uniformly associated with suppressive functions in CD4+ T 
cells201–203. 
 
Treg cells consist of two different subtypes of cells described in vivo: thymus-





Both classes of Treg cells can inhibit any step to the acquisition of effector 
functions of virtually any cell of the immune system. Their mechanisms of 
activity are the object of intensive research and seem to include cell contact 
direct cytotoxicity, deprivation of essential amino acids or growth factors from 
the environment, and secretion of soluble factors with inhibitory 
properties194,205. nTreg and iTreg cells seem to have similar but not identical 
transcriptomes206,207, and this may reflect functional disparities and non-
redundant roles207,208. Treg functions are associated with a peculiar 
epigenetic status of the Treg-specific demethylation region partially 
dependent by TGF-β209–211. This CpG hypomethylation pattern regulates the 
stability of FOXP3 expression and other specific Treg signatures and they are 
partly shared by nTreg and in vivo iTreg cells, but they are not detected in in 
vitro generated iTreg212. These observations highlight the close relationship 
between nTreg and in vivo generated iTreg, which are thought to cooperate 
to maintain immune homeostasis. 
 
nTreg cells develop in the thymus after interaction between MHC class II 
molecules and cognate TCR with high avidity213–215. They seem to have a 
crucial role in the maintenance of peripheral self-tolerance, as demonstrated 
by the observation that thymectomy in neonatal216 or adult217 normal animals 
results in the development of autoimmunity which can be reverted by the 
infusion of syngeneic CD25+ T cells216. Definitive evidence that these cells 
originate in the thymus and then persist in periphery has been provided by 
the finding that infusion of thymocytes depleted of CD4+CD25+ cells into 
athymic nude mice leads to several autoimmune diseases218. 
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In vivo generated iTreg cells are otherwise conventional CD4+ T cells which 
acquire FOXP3 expression and tolerogenic phenotype in periphery. 
Regardless of the specific condition considered, several different molecules 
can play a role for the generation of iTreg in vivo, including TGF-β, IL-2 or 
retinoic acid204,219. Similarly, also nTreg expansion can be promoted by 
different factors194. Among these factors, IDO can have important links with 
nTreg and iTreg cells biology. It has been demonstrated that DCs expressing 
IDO can mediate iTreg cell generation in vitro80,220, maintain their suppressive 
phenotype with inhibition of re-programming toward inflammatory functions 
both in vitro and in vivo221, and activate potent immunosuppressive properties 
in pre-existing, resting nTreg cells222. 
 
One of the properties of MSCs is the ability to generate a niche able to favour 
the expansion of Treg cells or their generation de novo, both in a direct or an 
indirect manner. Indeed, with the flourish of studies focusing on MSC 
immunosuppressive mechanism of action, it became apparent that part of the 
MSC activity can be associated with an increment of T cells with regulatory 
properties. Early studies demonstrated that MSCs in co-culture with both 
autologous or third-party PBMCs induced expansion of a population of CD4+ 
T cells with suppressing properties and co-expressing CD25 and CTLA-4223 
or CD25 and glucocorticosteroid-induced TNF receptor family member40, two 
markers upregulated in Treg cells224 and whose expression seems to be 
under the control of FOXP3225,226. These findings were confirmed in other 
studies where FOXP3 expression was detected in expanded CD4+CD25+ T 
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cells227,228. But the important role played by the MSC/Treg interaction has 
been comprehensively supported by the plethora of in vivo studies 
demonstrating a tight relationship between MSC therapeutic activity and Treg 
expansion. The robustness of this observation comes also from the fact that 
similar findings were reported by using different species and disease models. 
Indeed, Treg expansion following MSc treatment has been described in 
several pre-clinical models of autoimmune diseases174,229,238,239,230–237. 
 
In most of these studies the Treg importance in the MSC-mediated 
immunosuppression was evaluated indirectly, i.e. the loss of MSC efficacy 
was obtained by blocking those factors leading to Treg increase. 
Furthermore, the depletion of Treg cells from MSC recipient completely 
impaired the MSC therapeutic activity229,236. 
Importantly, it has to be noted that similar increase of the Treg cell population 
has been reported also in human patients after MSC administration. In their 
safety and feasibility pilot study on the use of autologous MSCs in patients 
receiving kidney allografts from living donors, Perico and colleagues240,241 
treated four patients and found that graft functions remained stable after 
transplant and MSC treatment, supporting the safety of the procedure. 
Importantly, all patients showed a progressive increase of the Treg 
population240,241. Similar findings were reported by Zhao et al. in a study 
where 28 patients affected by steroid resistant GvHD were treated with 
MSCs. Median MSC dose was 1x106/Kg body weight and the cells were 
infused weekly until complete response or when a maximum of 8 doses were 
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reached. Overall response rate was 75% and was significantly higher than 
what observed in a group of 19 similar patients but not treated with MSCs. 
Importantly, the monitoring of the immune cells in peripheral blood showed 
an increase of the level of Treg cells after MSC treatment in comparison with 
pre-treatment values in the same patients or with not-treated patients242. No 
analysis on the possible association between levels of Treg and response to 
MSCs was reported. 
 
Whether the increase of the Treg cells induced by MSCs is the result of the 
generation of new iTreg cells or conversely of the expansion of pre-existing 
nTreg is largely unknown. This is not a semantic problem. Indeed, a better 
understanding of the characteristic of these Treg cells would be important 
from a translational perspective and for understanding the mechanisms 
leading to durable clinical responses after MSC treatment. Indeed, the 
stability of iTreg tolerogenic phenotype can be highly variable and can be re-
programmed toward pro-inflammatory phenotypes194. Only few in vitro 
studies tried to address this question, and the observation that CD4+FOXP3+ 
could be obtained from CD4+CD25- cells suggest that, at least in specific 
culture conditions, MSCs can generate iTreg cells243,244. The very recent 
finding that Treg cells obtained from CD4+CD25- cells exhibit enhanced 
demethylation of the Treg-specific demethylation region245 seems to confirm 
the similarity of these MSC-generated iTreg cells with those described in vivo 




Another issue still subject of intense research is how the interaction between 
MSCs and T cells leads to the increase of Treg. While a few studies pointed 
out the requirement of cell contact175,188,243, in other studies this seems to be 
dispensable245,246. Furthermore, other findings suggested an indispensable 
and non-redundant role played by soluble factors such as TGF-β in 
vitro176,230,232,235 or IDO in vivo238, since the MSC-mediated increase of Treg 
cells was completely abrogated by means of TGF-β blockage using 
neutralizing antibodies230,232,235 and gene knock down176, or either IDO 
chemical inhibition or knock out engineering238, respectively. However, these 
latter studies did not directly address the necessity of cell-contact, thus 
leaving unanswered the question on the actual importance of this factor. 
 
MSCs can indirectly induce Treg cell expansion through interaction with other 
cells. An important aspect that should be considered is also the concomitant 
presence of other immune cells which can participate in the process of Treg 
expansion after being in contact or in close vicinity with MSCs. Indeed, in their 
study of the MSC-T cell interaction, English and colleagues demonstrated that 
Treg expansion could be obtained only by cell-cell contact via production of 
PGE2 and TGF-β, however the cell contact was dispensable when MSCs 
were mixed with an unfractionated population of PBMCs175. This apparent 
discrepancy could be explained by the role played by other mononuclear cells 
which, under instruction from MSCs, become mediators of the Treg 
expansion. Similar findings were reported by Patel et al., whereby the 
induction of Treg increase by MSCs was dependent on TGF-β produced by 
MSCs upon contact with breast cancer cells176. Furthermore, indeed, it has 
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been extensively shown that MSCs can modulate the activity of APCs 
(including macrophages83,116 or DCs244,247) leading them toward a regulatory 
phenotype which in turn mediate the development of Treg cells. 
 
MSCs are also capable to induce in vitro expansion of other T cells with 
regulatory properties, such as IL-10-secreting T regulatory type 1 (Tr1) and 
TGF-β-secreting T helper 3 cells (Th3) through the production of HO-1248. 
 
All these studies clearly demonstrate that Treg expansion is an important part 
of MSC immunosuppressive armamentarium. Several mechanisms can lead 
to Treg increase, much has been unveiled but more work is still needed for a 
comprehensive understanding of the relative importance of each factor in 
different inflammatory microenvironments or clinical settings. 
 
1.2.3.2 Education of the Mononuclear Phagocyte System (MPS) 
 
As seen in the previous paragraph, MSCs can orchestrate the expansion of 
a regulatory population of T cells, partly secreting those same factors which 
have potent suppressive activity also in a direct manner. Similarly, MSCs can 
also guide the generation of tolerogenic myeloid derived cells. These cells 
are grouped in what is defined the MPS. Historically, members of this system 
are DCs, monocyte-derived cells and tissue-resident macrophages249. When 
the MPS was conceived in early 70s250 and after the discovery of DCs251 and 
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their inclusion in this system252, these three types of cells were grouped 
together because of their phagocytic capacities and because it was thought 
that all originated by a common precursor, namely the circulating monocytes. 
In fact, it is now appreciated that monocyte-derived cells, macrophages and 
DCs belong to three different families of cells with different precursors. 
However, all share many overlapped functions249. 
 
Peculiarity of the cells of the MPS system is their extremely high plasticity and 
capacity to respond to environmental signals with a broad repertoire of 
effector functions. Indeed, shaped by surrounding cues, MPS cells can 
change their phenotypes and orchestrate the quantitative and qualitative type 
of immune response toward immunity or tolerogenesis induction. MSCs are 
able to interact with all cells of the MPS system and instruct them to acquire 
potent anti-inflammatory and immune suppressive phenotypes. 
 
1.2.3.3 MSC interaction with monocyte-derived cells and tissue-
resident macrophages 
 
Tissue resident macrophages and monocyte-derived cells are very close 
relatives. At least in a steady-state condition, tissue resident macrophages 
originate from precursors which migrate to peripheral tissues during 





Monocyte-derived cells are a heterogenous population of cells traditionally 
described as classical or non-classical monocytes. It has been demonstrated 
that classical monocytes derive from a common precursor258, whereas non-
classical monocytes seem to mainly patrol the vasculature bed and their 
ontogeny is still debated. 
 
Both populations of cells are highly plastic, and the essence of this complexity 
is expressed by the concept of macrophage polarization into M1 (or classical 
activation) and M2 (alternative activation), notion used to describe extreme 
phenotypic states resulting from a continuum of stimuli259. M1 macrophages 
were initially described as those induced in the presence of IFNγ combined 
with LPS or TNFα and mediated Th1 type responses with production of high 
levels of IL-1β, IL-12, reactive nitrogen intermediates, or reactive oxygen 
species. Conversely, M2 macrophages were induced in the presence of IL-4 
and IL-13, immunocomplexes, or IL-10 and produced IL-10, TGF-β, and 
polyamines, mainly mediating immune regulation, extracellular matrix 
remodelling and tissue repair, and Th2 responses259,260. It is now emerging 
as a far more complex process and this concept has been challenged and 
integrated with novel insights based on more advances in transcriptomics, 
proteomics and the use of genetically modified mouse strains which 
demonstrated the presence of entities with intermediate functions261. 
However, this dichotomy is very useful because it underlines the functional 
differences which monocyte-derived cells and macrophages can show 
depending on the specific microenvironment where they are activated. Thus, 
this terminology will be used in the rest of this dissertation, whereby the most 
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important factors driving a tolerogenic phenotype (M2 polarization) will be 
presented. 
 
MSCs can recruit monocytes at sites of injury and inflammation. In the 
presence of low doses of LPS or other TLR ligands in the bloodstream, MSCs 
are induced to express monocyte chemotactic protein-1 which is required for 
mobilization of monocytes from the BM in response to bacterial infections262. 
Once at the site of injury, factors produced by MSCs drove the differentiation 
toward an M2 phenotype of the recruited monocytes which eventually 
enhanced wound healing in a excisional wound healing model263. 
Several studies have confirmed the capacity of MSCs to promote M2 
polarization in vitro. BM-MSCs in co-culture of blood-derived monocytes 
induced upregulation of IL-10 and CD206 and downregulation of IL-12 and 
TNFα, all markers of M2 phenotype264. Similar results were obtained also 
using MSCs from other sources such as umbilical cord265 or gingiva266, thus 
highlighting that this important property is shared by MSCs from different 
origins. Notably, MSC-primed monocytes/macrophages seemed to be 
important in the anti-proliferative effect of MSCs in vitro, since macrophage 
depletion in the MSC/PBMC co-culture resulted in restoration of PBMC 
proliferation83,265. The mechanisms employed by MSCs to mediated the M2 
differentiation have been identified in the MSC production of IDO83, PGE2267, 
and IL-6268. However, more recently also a different mechanism has been 
proposed. In their study, Selleri and colleagues showed that MSCs were able 
to re-programme monocyte differentiation by secreting large amount of 
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lactate which eventually modified monocyte metabolism, thus leading to M2 
polarization. Reduction of lactate production by MSCs, completely abrogated 
this effect269. 
 
The ability of MSCs to educate monocyte-derived cells and macrophages has 
been confirmed in vivo. In their experiments, Nemeth et al. demonstrated that 
MSC effectiveness in reducing mortality or organ failure in a mouse model of 
sepsis was dependent on the presence of macrophages in MSC-treated mice. 
After activation of TLR4, MSCs were induced to produce PGE2 which 
stimulated IL-10 production in MSC-recipient macrophages through the 
interaction of PGE2 with its receptors EP2 and EP4. Macrophage depletion, 
inhibition of IL-10 or use of TLR4-/- MSCs completely abrogated the 
therapeutic effect of MSCs270. 
We have already discussed the role of TSG-6 in the MSC property to deliver 
immunosuppression in vivo. This effect is mediated by the activity of this 
molecule on the macrophage populations of MSC-recipient. In a mouse 
model of zymosan-induced peritonitis, a study of the Prockop’s group showed 
that MSC treatment was able to reduce macrophage infiltration in the 
peritoneum. This effect was mediated by MSC-derived TSG-6 which, upon 
interaction with CD44 on macrophage surface, hamper NF-κB translocation 
into the nucleus and transcription of inflammatory genes in macrophages132. 
The same group demonstrated the importance of these MSC-primed 
monocytes using a mouse model of corneal allotransplantation and 
experimental autoimmune uveitis. MSC treatment conferred protection 
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against both diseases and the beneficial effect was mediated by the increase 
of immune suppressive monocyte-derived cells induced by MSC-produced 
TSG-6. Notably, when MSC-conditioned monocytes were adoptively 
transferred into second animals, they showed therapeutic activity against 
both corneal rejection and uveitis271. 
 
1.2.3.4 MSC interaction with DCs 
 
DCs represent a heterogenous population of antigen presenting cells which 
are central in the homeostasis of immune system. Indeed, while its regulation 
of the adaptive immune system is well known, only recently an important role 
also in the innate responses has been decsribed272–274. Traditionally, DCs 
have been categorized in two distinct subgroups: plasmacytoid DCs 
(pDCs)275,276 and conventional or classical DCs (cDCs)249. 
 
As in monocyte/macrophage cells, contrasting functions (immunity versus 
tolerogenesis) can be demonstrated also in DCs. Indeed, in this subset of 
cells alteration of the process of maturation can lead to opposite outcomes. 
In the presence of inflammatory signals such as pathogen-associated 
molecular pattern molecules, damage-associated molecular pattern 
molecules or inflammatory cytokines, DC maturation is triggered, and these 
cells express high levels of MHC molecules in association of the co-
stimulatory molecules CD80, CD86 and CD40, secrete large amount of IL-12, 
and mediate T cell activation277,278. Conversely, in the presence of 
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suppressive cues (or in the absence of inflammatory stimuli) DCs maintain an 
immature phenotype and become strongly immunosuppressive275. 
 
DCs can exert their immunosuppressive activity not only by directly mediating 
differentiation of hypo responsive T cells but also inducing expansion of Treg 
cell populations. Indeed, cDCs were important in the support of nTreg 
development in the thymus through inhibition of nTreg apoptosis279, and 
pDCs from Peyer's patches stimulated with cytosine-phosphate-guanosine 
motifs were able to stimulate formation of iTreg from CD4+CD25- T cells280. 
 
The role of IDO in DC functions seems to be complex with opposite activities. 
While the production of IDO by DCs was suggested to be essential for the 
complete maturation and acquisition of chemotactic antigen presenting 
capacity in the presence of inflammatory stimuli281, IDO produced by DCs has 
been implicated in the generation of iTreg and tolerance induction282. Spleen 
tolerogenic cDCs have be shown to be responsible of the expansion of iTreg 
cells in vivo through the production of IDO, and these iTreg cells mediated 
the induction of oral tolerance to the fed antigen283. Importantly, Treg cells 
can also stimulate IDO production in DCs64,65, thus further contributing to the 
generation of an immunosuppressive milieu. 
 
The creation of such a microenvironment is the hallmark of MSC activity, as 
already described in previous paragraphs. It is then obvious that this MSC 
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capacity has also significant impact on DC ability to mature and to acquire a 
tolerogenic phenotype. 
MSCs can impair the differentiation of cDCs from CD34+ cord blood cells284 
or from peripheral blood monocytes in the concomitant presence of 
granulocyte-macrophage colony-stimulating factor plus IL-4 (conditions 
usually used to differentiate DCs from monocytes)285. DC maturation is 
completely impaired in the presence of MSCs with significantly reduction of 
expression of MHC proteins and co-stimulatory molecules285–288. 
Consistently, DC capacity to stimulate naïve T cell proliferation was 
weakened286–288. Notably, also in the presence of some features of 
maturation, such as a pro-immune IL-12/IL-10 secretion profile, DCs cultured 
in the presence of LPS and MSCs retained their phagocytic capacity and lost 
their capacity of form functional immunologic synapsis with T cells and 
stimulate activation of allogenic responses289. 
 
Several mechanisms have been described to explain how MSCs can mediate 
these effects with contrasting results. While a few studies found a dispensable 
role of cell-cell contact and pointed to IL-6 production as important mediator 
of MSC capacity to induce tolerogenic DCs286,287,290, others demonstrated 
how inhibition of other factors, such as TSG-6291 or PGE2292, could abolish 
this effect. Notably, a partial role of cell contact interactions has also been 
reported. Indeed, generation of regulatory DCs by MSCs was partly mediated 
by activation of Notch signalling pathway in a contact dependent manner288. 
Accordingly, Jagged-1 and Jagged-2293 have been described as playing a 
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role in the MSC/DCs interaction294,295. These discrepancies could be ascribed 
to the different experimental systems studied but also underline the possible 
redundancy of the different mechanisms. 
 
Several studies confirmed the crucial role of tolerogenic DCs in mediating the 
immunosuppression delivered by MSCs in vivo. After infusion, MSCs 
hampered the DC homing capacity to lymph nodes by reducing the 
expression of the CCR7 and CD49dβ1, two molecules important for DC 
trafficking. Importantly, these DCs were unable to prime CD4+ T cells in vitro 
and in vivo, and to cross present antigens to CD8+ T cells in vitro296. Infusion 
of MSCs in combination with low doses of rapamycin significantly prolong 
allogenic heart and skin graft survival. This effect was associated with 
increase of Treg cells and tolerogenic DCs in spleens of treated animals236. 
Similar data were also observed in humans. A significant increase of cDCs 
was observed in GvHD patients 2 weeks after MSC infusion which remained 
stable at later time points. A more pronounced increase of immature DCs was 
observed in those patients responding to MSCs when compared with non-
responding patients297. 
 
1.2.4 MSCs as tolerogenic and therapeutic agents 
 
The characteristics described in the previous paragraphs ignited the interest 
in MSCs, considered as promising tools to control aberrant inflammatory 
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responses by producing an immunomodulating environment. As shown in 
Figure 1.2, consultation of the public registry of clinical trials at the U.S. 
National Institute of Health database (at ClinicalTrials.gov) shows a 
continuous increase of the number of new studies involving MSCs for the 
treatment/prophylaxes of immune mediated diseases which were registered 
between 2004 and 2010, with at least 10 new registrations thereafter. 
 
The focus of this intensive research has been mainly centred around two 
aspects: 1) the use of MSCs to exert peripheral tolerance in contexts whereby 
this tolerance was altered after the use of MSCs (i.e. usefulness of MSCs as 
prophylaxes), and 2) the use of MSCs when an inflammatory or autoimmune 
response was already established before MSC infusion (i.e. MSC use as 
proper therapy to restore peripheral tolerance).
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Figure 1.2. MSCs as therapeutic agents in immune-mediated diseases. 
Number of Clinical trials registered at the U.S. NIH database registry 
(ClinicalTrials.gov) plotted according to the year of registration. Search was 
performed in February 2018 and included all studies whereby MSCs 
(Mesenchymal Stromal/Stem Cells) were used as drug for the treatment of 
GvHD or other immune-mediated diseases. Other diseases included: 
inflammatory lung diseases (including asthma and Chronic Obstructive 
Pulmonary Disease), Chron’s Disease, Ulcerative Colitis, Systemic Sclerosis, 
Rheumatoid Arthritis, Rheumatic arthritis, Diabetes Mellitus, Cystic Fibrosis, 
Multiple Sclerosis, solid allograft rejection, Retinitis Pigmentosa, Sjogren 
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1.2.5 MSCs and its use as second line GvHD therapy 
 
GvHD is a life-threatening complication of allogeneic HSCT, and currently 
represents one of the major factors limiting the success of this potentially 
curative option for haematological malignancies298,299. GvHD develops when 
donor alloreactive T cells respond to host antigens300. The most important 
factor determining GvHD frequency is the disparity of HLAs repertoire 
between donor and recipient301. However, also patients receiving fully HLA 
matched donor cells can develop GvHD. This depends on the recognition of 
minor histocompatibility antigens302, allelic or sex-linked polymorphisms that 
act as transplantation antigens. Furthermore, genetic polymorphisms of 
genes encoding cytokines303,304 or proteins involved in innate immune 
responses305 can also contribute to increase the incidence of GvHD. 
 
GvHD has been classified into acute (aGvHD) and chronic (cGvHD). 
Traditionally, aGvHD was defined as arising by day 100 after HSCT, while all 
forms developing after that cut-off were considered as cGvHD298. However, 
clinical manifestations of aGvHD could persist or develop later than the first 
three months and symptoms of aGvHD could arise in patients with pre-
existing cGvHD. To address these issues, the National Institutes of Health 
Consensus Conference on GvHD proposed306, and subsequently refined307, 
a set of standardized criteria for the diagnosis and scoring of the severity of 
GvHD based on the assumption that only clinical features should define 




aGvHD consists in: 1) classic aGvHD, occurring within the first 100 days after 
HSCT; and 2) persistent, recurrent or late-onset aGvHD, incorporating those 
aGvHD forms arising after that time cut-off. 
Organs typically involved in aGvHD are skin, liver and gut. However, a serious 
clinical syndrome resulting from diffuse and non-infectious lung injury has 
been described early after HSCT and is not recognised as manifestation of 
cGvHD308–310. This complication, termed idiopathic pneumonia syndrome, 
responds poorly to conventional treatments. Although histologic criteria of 
GvHD diagnosis are difficult to be met in lungs, there is accumulating 
evidence which supports the notion that also lung should be included among 
the target organs of aGvHD311,312. 
aGvHD complicates HSTC in 35-80% of transplanted patients, depending on 
the HLA mismatch between recipient and donor, source of haematopoietic 
stem cells, transplant conditioning regimen, and GvHD prophylaxis298. The 
severity of aGvHD is determined by using a scale of 4 grades based on the 
involvement and extent of the three main target organs: I (mild), II (moderate), 
III (severe) and IV (very severe). Grade III and IV aGvHD are those with the 
poorest prognosis with median overall survival between 25% and 5% at 5 
years from GvHD diagnosis, respectively298. Apart from grade I skin aGvHD 
which is treated with topic steroids, treatment of choice of aGvHD is the use 
of systemic steroids at high doses with 60-80% of the patients responding to 




cGvHD is the most important long-term complication after allogenic HSCT, 
significantly affecting the quality of life of patients and with negative impact 
on their survival314. Its frequency varies between 30% to 70% of transplanted 
patients, depending on several factors including prior aGvHD diagnosis, type 
of transplant and source of haematopoietic cells315. cGvHD is divided in: 1) 
classic cGvHD, developed after 100 days and without concomitant symptoms 
of aGvHD; and 2) overlap syndrome, which includes all patients with 
diagnosis of cGvHD presenting concurrent manifestations of aGvHD 
(independently of the temporal relation with cGvHD)307. 
cGVHD is a syndrome characterised by variable manifestations which recall 
other known autoimmune disorders, such as bronchiolitis obliterans, chronic 
immunodeficiency, scleroderma, primary biliary cirrhosis, Sjögren’s 
syndrome, or immune cytopenias306,307. 
Albeit the pathophysiology of cGvHD remains poorly defined, recent findings 
suggest a crucial role of naïve T cells dysregulation which leads to thymus 
damage and alteration of the antigen-presenting processes in the periphery. 
These initial factors would lead to the generation of aberrant T and B cell 
responses, production of auto and alloantibodies, and the activation of 
macrophages with deposition of extracellular matrix and development of 
fibrosis316. Manifestations of cGVHD are broadly variable and may be 
localized to a single site or be widespread, they can be self-limited and/or 




1.2.5.1 The role of MSCs for the treatment of aGvHD 
 
Currently, there is no standardized treatment for patients who do not respond 
to steroids and their prognosis is still very poor, with overall survival inferior 
to 20% at 2 years317. 
 
Thanks to their potent immunosuppressive activity in vitro, and after the report 
that a patient with grade IV GvHD resistant to several lines of treatment was 
able to achieve a dramatic improvement after multiple infusions of third-party 
MSCs in 200426, the interest in using MSCs in GvHD patients has sparked 
remarkably. Since then, at least one new clinical trial involving the use of 
MSCs to mitigate GvHD has been registered every year at ClinicalTrial.gov 
with a peak of 5 different studies started in 2015 (Figure 1.2). To date (last 
analysis in October 2018), a systematic search of the literature which includes 
both retrospective and interventional studies on the use of MSCs to treat 
aGvHD has identified 24 different studies with at least 10 patients enrolled 
(Table 1.1). 
When also small case reports318–326, a total of 835 aGvHD patients have been 
reported as treated with MSCs and more than 1000 MSC doses administered. 
Both paediatric and adult patients were treated with age ranging from 2 
months to 72 years. 
All aGvHD patients were steroid resistant. Only one study used MSCs as first 
line treatment in association with steroids327. 
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MSCs could successfully be expanded from disparate tissues, spanning from 
BM242,297,329–338,319,339–345,320–322,325–328, umbilical cord (UC)318,346, adipose 
tissue (AT)323,324, or placenta347. While BM has been the first MSC source 
ever described and the most employed thus far, this data is remarkable since 
umbilical cord and adipose tissue may be considered more “affordable” 
alternative sources in terms of manufacturing logistics and costs in 
comparison with BM. Indeed, obtaining MSCs from UC or AT tissues has 
important advantages. First, the invasive BM harvest procedure, associated 
with (minimal) risk for donors, can be spared. Secondly, both UC-MSCs and 
AT-MSCs can be obtained from tissues which are currently otherwise 
discarded, and, at least for UC, also from samples previously frozen before 
isolation348,349. Third, they have higher proliferative capacity and longer life-
span in vitro with higher cells yielded per expansion37,350. As already 
described in the paragraph describing the MSC immunobiology, the origin of 
the MSCs does not seem to affect their anti-proliferative and immunological 
properties in vitro. The data reported in these studies, despite the small 
number of patients treated with UC318,346, AT323,324 or placenta347, have shown 
similar response rates to those reported in similar studies where BM-MSCs 
were used (Table 1), thus supporting the role of these sources as valid 
alternatives for clinical-grade MSC production. 
 
MSC use in aGvHD seems to be safe, since no acute adverse reactions 
related to MSC infusion have been reported, regardless the source of the 
MSC used, the treatment schedule or MSC dose. These findings further 
confirmed a previous comprehensive meta-analysis performed on 8 different 
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controlled clinical trials, whereby MSCs were used for the treatment of several 
diseases (including GvHD, stroke, cardiomyopathy, solid organ transplant 
and healthy volunteers). The studies reported were performed in 14 different 
countries in Asia, the Middle East, Europe, and North America. The meta-
analysis did not find any association between MSC administration and acute 
infusional reactions, organ complication, infections or death351. The potent 
immunosuppressive properties of MSCs raise serious concerns on the 
residual ability of the patient to respond to infections and the underlying 
malignancy. In their study, Zhao and collaborators prospectively compared 
the frequency of infectious episodes (including Epstein–Barr virus and 
Cytomegalovirus reactivations) and cancer relapses in MSC-treated and non-
treated patients with a follow-up of one year and did not find any difference 
between the two groups242. Another group found that both the incidence of 
virus reactivations and latency from the start of steroid treatment were similar 
in patients treated with MSCs and historical controls332. Interestingly, the 
competing risk analysis to test the likelihood of infection or death during the 
first 100 days after MSC infusion found no difference between MSC 
responders and non-responders297. These findings are corroborated by the 
available published data which support the notion that MSCs do not lead to 
an increase in both infection severity or frequency, or number of relapses in 
MSC treated patients337,338,341, when compared with similar cohorts of 
patients but treated with different treatments352. 
 
Outcomes of patients treated with MSCs in the reported studies are 
summarized in Table 1. It is not possible to directly compare these studies 
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due to the heterogeneity of the patients enrolled. Furthermore, while most of 
the studies were prospective242,297,336–342,321,322,327,329,331–334, some of them 
were retrospective325,328,330,335,343–345,347 or case reports318,319,323,324,326,353. 
However, data on MSC efficacy have been extremely encouraging with 
overall response rates between 33% and 100% (median 72%). Broad 
variations were reported regarding patients’ overall survival (OS). Although a 
few studies showed an OS at 2 years after first MSC infusion between 17% 
and 35%329,338,339,343,345, most of them reported an increase of the survival of 
patients after treatment with MSCs, with OS rates ranging from 40% up to 
76%242,297,337,340,341,320,327–331,334,336. 
 
Despite the broad variability in the terms of outcomes, there is a remarkable 
homogeneity on the results in every study when the OS is considered in the 
sub-categories of responding and non-responding patients. Indeed, patients 
who responded to MSCs consistently exhibited a significantly longer OS, with 
survival rates at 2 years higher than 50%297,320,327–331,339.
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  Patients MSC Outcome 
Publication N Median age (range) 
Source/                         
n of donors 
Dose (x106/Kg) 
Number of Infusions        
Median (range) 
CR (%) PR (%) NR (%) 
Prasad, 2011328 12 5 (0,4-15) BM/4 2.00-8.00 8 (2-21) 17 50 33 
LeBlanc, 2008329 55 22 (0.5-64) BM/45 0.40-9.00 2 (1-5) 54 16 29 
Ball, 2013330 37 7 (0.7-18) BM/NRe 0.90-3.00 2 (1-13) 65 22 13 
Kurtzberg, 2014331 75 8 (0.2-17) BM/7 2.00 NRe (8-12) NRe NRe NRe 
TeBoom, 2015297 48 44.9 (1.3-68.9) BM/multiple 1.80 (0.90-2.50) 3 (1-4) 25 50 25 
Chen, 2012346 19 NM UC/NRe 0.60-7.00 NRe 58 21 21 
Kebriaei, 2009327 31 52 (34-67) BM/multiple 2.00-8.00 2 (2) 77 16 7 
Erbey, 2016335 33 7 (3-18) BM/68 0.50–2.80 2 (1-4) 54 21 25 
Muroi, 2013336 14 52 (4-62) BM/multiple 2.00 8 (8-12) 57 36 7 
Muroi, 2016337 25 35 (5-66) BM/multiple 2.00 8 (4-16) 24 36 40 
Sanchez-Guijo, 2014342 25 NM (20-65) BM/24 1.10 (0.70-1.31) 4 (2-4) 44 26 30 
Servais, 2018339 33 58 (5-69) BM/multiple NRe (1.00-4.00) 1 (1-2) 22 41 37 
Lucchini, 2012332 11 NM BM/multiple 1.00 NRe 18 36 46 
Perez-Simon, 2011333 10 37 (21-62) BM/multiple 1.00-2.00 NRe (1-2) 10 60 30 
Herrmann, 2012334 12 48.5 (21-61) BM/16 1.70-2.30 2 (2-19) 58 33 9 
vonDalowski, 2016338 58 55 (19-71) BM/multiple 0.99 (0.45-2.08) 2 (1-6) 9 38 53 
Dotoli, 2017345 46 28 (1-72) BM/NRe 6.81 (0.98-29.78)** 3 (1-7) 7 43 50 
Bader, 2018340 69 
8.2 (0.5-18)                               
45.5 (18.9-65.5) 
BM/pooled NRe (1.00-2.00) NRe (1-4) 32 51 14* 




Table 1.1. MSC use in aGvHD: characteristics of each study. 
 
 
BM: Bone Marrow. CR: Complete Response. DC: Decidual Cells. NR: No Response. NRe: Not reported. PR: Partial Response. UC: 
Umbilical Cord. *: 3%, no data available at day 28. **: cumulative dose.
Salmenniemi, 2017343 26 
8 (12-14)                                       
45 (21-66) 
BM/NRe 2.00 (1.40-2.70) 5 (1-6) 27 34 39 
Resnick, 2013344 50 19 (1-69) BM/multiple 1.00 (0.3-3.10) NRe (1-4) 34 32 34 
Zhao, 2015242 28 26 (14-54) BM/multiple 4.00 (2.00-8.00) 1 (NRe) 37 29 34 
Ringden, 2018347 17 54.5 (0.9-65.6) DC/NRe 2.00 (0.90-2.80) 1 (1-5) 30 29 41 
Ringden, 2018347 21 48.9 (1.6-72.4) DC/NRe 1.20 (0.90-2.90) 2 (1-6) 52 48 0 
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1.2.5.2 The role of MSCs for the treatment of cGvHD 
 
Therapeutic options in cGvHD are limited and mainly based on the use of 
steroids as first line. Results are disappointing, because of the significant 
toxicity due to the prolonged use of systemic corticosteroids. Furthermore, 
50%-60% of the patients require a second immunosuppressive agent354. 
Although several treatments have been used as second line, none of them 
has proved its efficacy, thus consensus on how two manage resistant patients 
is still lacking. 
 
To try to address this unmet need, MSC therapeutic activity has been tested 
also in cGvHD, albeit the experience in this setting is more limited than in 
aGvHD. Indeed, most studies reported the treatment of only few patients, and 
they should be considered as case reports. Results were variable, with overall 
responses ranging from 0%341,343 to more than 50% of the patients 
treated325,333,334,355. More promising are the results obtained from larger group 
of patients and reported in three different studies. In two of these studies a 
total of 57 steroid-refractory cGvHD were treated with 1 to 5 infusions of BM-
MSCs. The median time to response varied between 3 to 24 months after the 
first MSC infusion356,357. Notably, 26% of the patients treated could wean 
immunosuppressive therapy until complete discontinuation in one of the 
studies357. Recently, 14 patients with moderate to severe cGvHD were 
prospectively treated with one infusion of AT-MSCs as first-line treatment in 
association with steroids and cyclosporine358. In total 13 patients could be 
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evaluable, since 1 patient withdrew participation consent. Ten patients 
achieved a response at 56 weeks (8 complete response [CR] and 2 partial 
response [PR]), all had stopped steroids and were alive at the end of the 
study. Conversely, of the three non-responding patients, none was alive and 
the cause of death was progressive cGvHD358. 
 
1.2.5.3 MSCs as prophylactic agent against GvHD 
 
MSCs have been demonstrated to enhance haematopoietic engraftment and 
haematological recovery after both autologous24 and allogenic359–361 HSCT 
when administered at the time of transplant. These findings, along with 
positive results from preclinical models whereby MSCs were able to delay the 
onset of GvHD362,363, prompted investigators to assess whether MSCs could 
be used prophylactically to decrease the frequency of GvHD when co-
administered with the transplant. A comprehensive meta-analysis carried out 
by Kallekleiv et al364 determined the potential benefits of MSCs when co-
administered with allogenic HSCT within a range of 24 hours (before or after 
the transplant). The study included a total of 309 patients enrolled in 9 
controlled trials performed until May 2015, thereof 3 randomized and 6 non-
randomized studies. The analysis suggests that MSCs do not have any 
beneficial effects in terms of reduction of either aGvHD nor cGvHD, also when 
patients were sub-categorized into grade I-II or III-IV aGvHD or moderate to 
severe cGvDH364. Important limitation of this meta-analysis relates to the 
small sample sizes of the studies included and their weak designs, thus 
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results should be interpreted with caution. However, the evidence provided 
seems not to support the routinely use of MSCs as GvHD prophylactic agents 
when co-transplanted with HSCs. 
 
These data are in line with the notion of “licensing” of the MSC 
immunosuppressive properties already described in the paragraph dedicated 
to the immunobiology of MSCs. This concept finds support not only in vitro 
but also in preclinical models of GvHD, whereby MSC therapeutic activity 
could be obtained only when MSCs were infused in the presence of a specific 
inflammatory milieu52. Accordingly, MSCs were effective in reducing GvHD 
signs only when multiple infusions were administered after transplant but not 
when one single dose was co-infused with HSCT365. These experimental 
observations have been strongly supported by a meta-analysis recently 
performed by Wang and collaborators366. In this work, the authors extended 
the previously cited meta-analysis performed by Kallekleiv364 with three larger 
randomized clinical trials. The research was performed until January 2018 
and included 6 randomized clinical trials enrolling 365 patients. MSCs were 
infused at different time points from HSCT (within 24 hours, at a median time 
of 28 days, or with multiple infusions at different time points). The analysis 
showed that infusion of MSCs significantly reduced the incidence of cGvHD 
and there was a trend of longer OS in MSC-treated patients366. Importantly, 
the meta-analysis on different sub-groups demonstrated that these 
favourable outcomes were significantly associated with late MSC 
administrations, thus supporting a more effective role of MSCs when licensed 




1.2.6 Summary and future challenges in MSC-based therapy 
of GvHD 
 
MSCs have very potent immunosuppressive activity against any cell of the 
immune system. 
Their immunobiology makes them ideal candidates for their use in cellular 
therapy in several immune mediated diseases, including GvHD1. The MSC 
ability to reduce GvHD is conserved across MHC barriers367. This observation 
is confirmed by clinical data in humans, whereby the use of MHC-matched, 
haploidentical or third-party MSC donors does not have any impact on patient 
outcomes (see previous paragraph 1.2.5, and Table 1.1). 
 
After thousands of infusions the most convincing conclusion is that MSC 
infusions are well-tolerated. Major infectious events or disease relapse do not 
seem to increase after MSC therapy351,366. Furthermore, responding patients, 
who presented complete disappearance of GvHD symptoms or a reduction 
of their GvHD clinical scores, survive much longer than those patients 
presenting stability or progression of GvHD after MSC therapy (thus defined 
as non-responders). Notably, achievement of a response is associated with 
a predicted OS at 2 years of more than 50%, remarkable result if the poor 




Despite these very encouraging results, conclusive proof of efficacy has not 
yet been provided, and the only randomised phase III trial, making use of 
commercially available MSCs (Prochymal, Osiris), missed its endpoint 
(improvement of CR at day 28 after MSC infusion in comparison with placebo 
treated patients). However, this failure was only announced by press-release 
and results never published in a peer-reviewed manuscript. Intense 
arguments on the efficacy of MSCs in GvHD has been ignited in the last few 
years368, and the recent clinical commissioning policy on GvHD treatments 
published by NHS England concluded that there was not enough evidence 
for supporting the use of MSCs in GvHD patients369. 
 
These considerations highlight an unmet need to better understand how to 
improve the durability and the rates of responses to MSCs in GvHD patients. 
Insofar, any step forward has been undermined by our poor knowledge of 
how MSCs deliver their therapeutic activity. As described in this Chapter, 
many mechanisms have been described. However, none of them have been 
translated into effective tools which can be implemented to ameliorate clinical 
outcomes of the patients treated. This aim can be achieved only by moving 
back from bed to the bench and by the reconsideration of the mechanisms 
employed by MSCs to deliver their therapeutic properties in vivo32,370. Filling 
the gaps in our understanding on how MSCs actually mediate 
immunosuppression in vivo will translate into the discovery of effective 
potency assays or biomarkers which will guide patients’ stratification and help 
the prediction of their clinical outcomes. Importantly, the implementation of 
these biomarkers will guide investigators toward well-designed prospective 
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phase III clinical trials, with whom robustly and definitely assessing where 
MSCs should be placed in the GvHD therapy armamentarium. 
 
Furthermore, only unravelling these mechanisms will allow the identification 
of the necessary tools to harmonize the broad heterogeneity among MSC 
manufacturing processes across different centres371, which is a crucial pre-
requisition for rigorous and scientifically acceptable comparison between 
different MSC preparations and for reproducibility across studies. 
 
1.2.7 General hypothesis 
 
We hypothesise that crucial steps for improving the use of MSCs for the 
treatment of GvHD are the following: 
1. Decipher how MSCs deliver their therapeutic activity in vivo early after 
infusion, starting from the observation that MSCs do not engraft in the 
recipient. 
2. Identify mechanistic biomarkers which can be used to predict the 
clinical outcomes of the patients 
 
1.2.8 Key objectives 
 




1. The fate of MSCs after infusion. In details, we tested whether MSCs 
undergo apoptosis after administration. 
 
2. The role of apoptosis in the therapeutic activity of MSCs. In particular, 
we tested whether the apoptosis hampered MSC efficacy or was 
instrumental in the immunosuppressive activity of MSCs. 
 
3. The factors associated with the induction of MSCs apoptosis in vivo. 
 
4. The validity of these factors for the identification of suitable biomarkers 
able to predict the clinical outcome of GvHD patients. In details, the 
biomarker will be tested in a cohort of patients treated with MSCs, and 
its association with the clinical response assessed after one week from 
MSC infusion. 
 
5. The validity of the assessment of the response at one week after MSC 
infusion as predictor of treatment failure/success. This will be tested 
by analysing the overall survival times of aGvHD patients treated with 




2 Material and Methods 
 
2.1 Mice and disease models 
 
C57BL/6 (H2b) and Balb/C (H2d) mice were purchased from Harlan 
Laboratories. Matahari (Mh) (C57Bl/6 background, CD8+Tg, H-2b, CD45.2+, 
H-2Db-restricted)372 mice are transgenic for a TCR specific for the male 
antigen UTY presented in the context of H-Db. Mice were bred in-house and 
maintained at the Biological Service Unit of the Royal Free and University 
College London Medical School (London, UK) and of Charles River UK Ltd. 
All mice were used between 6 and 12 weeks of age. 
 
aGvHD was induced as previously described373. Briefly, after lethal irradiation 
(11 Gy), recipient C57BL/6 male mice were transplanted with 1x106 purified 
CD8+ T cells from female Mh mice, 5x106 unfractionated BM and 2x106 
purified CD4+ T cells from female C57BL/6 wild-type donors. The control 
group received BM and purified CD4+ cells only. CD4+ and CD8+ T cells were 
obtained by positive selection using magnetic beads (Miltenyi Biotec Ltd). 
Live human MSCs (1x106) were injected intravenously (i.v.) at day +3, whilst 
MSCs made apoptotic in vitro (ApoMSCs) (1x106) were administered i.v. or 
intraperitoneally (i.p.) at day +1, +3 and +6 from the transplant. Unless 
otherwise specified, animals were euthanized for analysis at day +7. The 
infiltration of GvHD effector cells was assessed by flow-cytometry and the 
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percentage was expressed as proportion of cells in the lymphocyte gate, 
based on the physical characteristics of the cells. 
 
For the depletion of all phagocytes mice received 1 mg liposome clodronate 
(ClodronateLiposomes.com) i.v. 72 hours before MSC infusion374. Recipient 
IDO activity was inhibited by using 1-methyl-D-tryptophan (1-DMT) treatment 
(Sigma-Aldrich Company Ltd) (2mg/ml) in the drinking water starting from 6 
days prior to MSC injection until animals were sacrificed375. 
C57BL/6-Prf1tm1Sdz/J (Perforin-/-) mice were purchased from Jackson labs, 
bred with Matahari Rag2-/- mice and the resulting offspring intercrossed for 2 
generations to obtain Mh Rag2-/-/Perforin -/- F3 mice. 
 
OVA-induced airway inflammation was induced as previously described376. 
Briefly, female Balb/C mice (Harlan Laboratories) were injected i.p. with 30 
µg of chicken egg albumin (OVA type V) (Sigma-Aldrich Company Ltd) on 
day 0 and 7. Controls received vehicle (aluminum hydroxide) only. On day 
14, 15 and 16 animals were challenged with an aerosolized solution of OVA 
(3%) for 25 minutes. MSCs or ApoMSCs were injected 1 hour after the last 
challenge. After additional 18 hours, mice were terminally anaesthetized with 
urethane (2 g/kg i.p.) (Sigma-Aldrich Company Ltd), a cannula inserted into 
the exposed trachea and three 0.5 mL aliquots of sterile saline were injected 
into the lungs. The total number of cells in the lavage fluid was counted. For 
differential cell counts, cytospin preparations were stained with Diff Quick 




In all experiments, animals were randomly allocated to control or 
experimental groups. No blinding approach was adopted. Animal procedures 
were carried out in compliance with the UK Home Office Animals (Scientific 
Procedures) Act of 1986. 
 
2.2 Cell preparations and media 
 
Cultures were carried out in complete Roswell Park Memorial Institute 
medium (RPMI) 1640 medium containing GlutaMAXTM, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (25mM), Penicillin 5000 U/ml and 
Streptomycin 5000 µg/ml (ThermoFisher Scientific), foetal bovine serum 10% 
(Labtech.com). 
 
Human peripheral blood samples from healthy donors were procured by the 
National Blood Service (Colindale, UK) as leukocyte cones. Samples from 
GvHD patients were collected within 24 hours before MSC injection. Informed 
consent was obtained in accordance with the local ethics committee 
requirements. PBMCs were isolated by density gradient separation on 
Histopaque-1077 (Sigma-Aldrich Company Ltd,). 
 
Murine splenocytes were isolated through a cell strainer (BD Falcon), whilst 
lungs were cut into small pieces and incubated with Collagenase type IV (250 
U/ml) (Lorne Laboratories), deoxyribonuclease I from bovine pancreas (250 




2.3 MSC preparations 
 
Clinical grade BM-derived human MSCs were generated from BM aspirates 
collected from the iliac crest of 2 healthy donors. Briefly, 2 ml of BM aspirate 
were collected in a tube with 100 µl preservative-free heparin. The cells were 
plated within 24 hours at a density of 10-25 million/636 cm2 by using alpha 
modified Eagle’s medium (ThermoFisher Scientific), conservative-free 
heparin (1 UI/ml) (Wockhardt UK Limited) and 5% platelet lysate and then 
incubated for 3 days at 37 °C and 5% CO2 ambience. Non-adherent cells 
were discarded by washing with phosphate buffered saline (ThermoFisher 
Scientific). When cell confluence of 90-100% was achieved, cells were 
detached with Trypsin- Ethylenediaminetetraacetic acid (EDTA) (0.05% 
trypsin, 0.5γ mM EDTA•4Na) (ThermoFisher Scientific) and reseeded at a 
density of 5000 cells/cm2. MSCs were used at passage 2 for all in vivo 
experiments, whilst they were used by passage 8 for the in vitro experiments. 
In the latter case we did not observe any difference in terms of apoptosis 
susceptibility between different passages. Released criteria were based on 
positivity (>80%) for CD105, CD90, CD73, negativity (<2%) for CD3, CD14, 
CD19, CD31, CD45. In each experiment, MSCs were derived from a single 
expansion and not pooled. 
 
MSCs used for the treatment of the patients enrolled in this study were 
manufactured at Imperial College Healthcare NHS Trust or at the University 
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Hospital Carl Gustav Carus, Dresden for those patients treated in the UK or 
Germany, respectively. 
 
ApoMSCs were obtained by plating 5x105 cells per well in a 96 round-bottom 
well plate in the presence of synthetic human Granzyme B (GrB) (5 µg/ml) 
(Enzo Life Sciences) and anti-FAS human (activating, clone CH11) (10 µg/ml) 
(Merk Millipore) for 24 hours in complete RPMI. The concentration of GrB and 
FasL was chosen to produce at least 80% of MSC apoptosis. 
 
2.4 Patient details 
 
For the study of the cytotoxic assay, a cohort of 32 patients affected by steroid 
resistant GvHD was studied. Patients were enrolled between November 2012 
and December 2017, they were treated with MSCs in the Department of 
Haematology at Imperial College London, Southampton University Hospital, 
Bristol Haematology and Oncology Centre, Manchester University Hospital, 
and the University Hospital Carl Gustav Carus, Dresden. MSCs were 
administered for compassionate use (according to Regulation (EC) No 
1394/2007). The diagnosis of GvHD was made on histological criteria and 
GvHD staged according to standard criteria377,378. Patients were considered 
to be steroid-refractory if: (a) those with aGVHD failed to respond to high-
dose methylprednisolone after 6 days; (b) the one with cGVHD failed to 
respond to high-dose steroids after 2-4 weeks, with the addition of 
Mycophenolate Mofetil (MMF) and cyclosporine (CSA) at 1 and 4 weeks 
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respectively. Clinical responses to MSCs were assessed 1 week after MSC 
infusion and defined as an improvement of at least 50% in at least one organ 
affected by GvHD. Patient characteristics are summarized in Table 3.1. 
 
To verify the clinical validity of the assessment of the response to MSCs after 
1 week from infusion, the retrospective analysis of the data of a cohort of 60 
patients was carried out. Of these patients, three were included in the study 
of the cytotoxic assay. 
The patients included in this analysis were affected by steroid resistant 
aGvHD and treated with BM-MSCs between May 2008 and December 2014 
at the following UK centres: King’s College Hospital NHS Trust, Imperial 
College Healthcare NHS Trust, London, Central Manchester University 
Hospital, Manchester, University Hospitals Bristol, Bristol, University Hospital 
Southampton, Southampton, Birmingham Women’s and Children’s Hospitals, 
Birmingham, The Christie NHS Foundation Trust, Manchester, London, Royal 
Hallamshire Hospital, Sheffield, Sheffield Children’s Hospital, Sheffield, Heart 
of England NHS Foundation Trust, Birmingham and Plymouth Hospitals NHS 
Trust, Plymouth. Patient characteristics are summarized in Table 5.1. 
 
2.5 Imaging of MSCs 
 
MSCs were transfected using electroporation (Gene Pulser Xcell, BioRad). 
Cells were suspended in a total volume of 250 µl of buffer and electroporated 
in 0.4 cm gap cuvettes using 10 µg of DNA at 250 volts and 950 F. Vectors 
used for transfection were the pGL3-Control vector containing the SV40 
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promoter for the expression of Luc+ (Promega) or the pECFP-DEVDR-Venus 
(Addgene). When pECFP-DEVDR-Venus was used, the donor fluorophore 
pECFP and the acceptor Venus-YFP were linked through the flexible linker 
DEVDR which is recognized and cleaved by the active form of caspase 3. In 
this system, caspase 3 activity can be monitored through the analysis of the 
Förster Resonance Energy Transfer (FRET) between pECFP and Venus-
YFP. When caspase 3 is not active, the flexible linker DEVDR remains intact 
and energy transfer from pECFP is allowed with emission of YFP signal. 
Conversely, in the presence of caspase 3 activation DEVDR is cleaved, thus 
energy transfer is lost and the pECFP signal increases. 
 
For confocal imaging, pECFP-DEVDR-Venus transfected MSCs were plated 
in complete RPMI at a concentration of 1x105 cells in a 30 mm x 10 mm dish 
(Corning) and let adhere overnight. The following day PHA-aPBMCs were 
added at a PBMC:MSC ratio of 40:1. Where indicated, pan caspase inhibitor 
carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone (Z-VAD-
FMK) (50 µM), perforin inhibitor ethylene-bis(oxyethylenenitrilo)tetraacetic 
acid (EGTA) (4 mM), GrB-inhibitor methyl-5-chloro-4-oxo-3-[2-[2-
(phenylmethoxycarbonylamino) propanoylamino] propanoylamino] 
pentanoate (Z-AAD-CMK) (300 µM) were used. Living cell imaging was 
acquired every 3 minutes for 180 minutes using a Leica TCS-SP5 II Confocal 
Microscope, with 488 nm and 407 nm lasers. The images were processed 




In vivo imaging was performed injecting i.v. 1x106 MSCs transfected with 
luciferase (luc-MSCs) into naïve C57BL/6, BM or GvHD mice 3 days after the 
transplant in the GvHD model. In the airway inflammation model, luc-MSCs 
were infused i.v. in naïve Balb/C or OVA-treated mice 1 hour after the last 
OVA challenge. After one additional hour, mice were anesthetized with 
isoflurane (1.5% isofluorane, 98.5% Oxygen), injected i.p. with 3 mg of 
VivoGlo Casp 3/7 substrate Z-DEVD Aminoluciferine (Promega,) and imaged 
using IVIS® Lumina III (PerkinElmer) system for a total time of 5 minutes. 
Images were analyzed by using the software “R” and EBImage package to 
obtain mean total luminescence signal (TLS). Confirmation of the presence 
of transfected MSCs was obtained injecting mice with VivoGlo Luciferin 
(Promega) 30 minutes after the administration of substrate Z-DEVD 
Aminoluciferine. 
 
2.6 Detection of efferocytosis 
 
MSCs were first labelled using CellTrace Violet labelling (ThermoFisher 
Scientific) at a final concentration of 5 µM and then made apoptotic 
(ApoMSCs) as described above, using synthetic human GrB (5 µg/ml) and 
anti-FAS human (10 µg/ml) for 24 hours. 10x106 labelled apoMSCs were then 
injected i.p. or i.v. and mice sacrificed after 2 hours post-injection. Spleen, 
lungs, peritracheal, paratracheal, pericardial, mesenteric, periportal and 
celiac lymph nodes were collected and analysed by flow-cytometry. Positivity 
of CellTrace Violet was assessed as measure of ApoMSC engulfment in 
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CD11b+ and CD11c+ gated subpopulations of phagocytic cells. Cells positive 
for the CellTrace Violet were then assessed for their expression of IDO. 
 
2.7 Pre-activation of human PBMCs and murine CD8+ cells 
 
PBMCs pre-activated with phytohemagglutinin (PHA) (PHA-aPBMCs) were 
obtained plating 5x106 human PBMCs in 24-well plate in the presence of PHA 
(5 µg/ml) (Sigma-Aldrich Company Ltd) in a final volume of 2 ml of complete 
RPMI for 72 hours. PBMCs pre-activated with MLR (MLR-aPBMCs) were 
obtained using one-way MLR in which PBMCs from one donor (stimulators) 
were irradiated (30 Gy) and co-cultured with the PBMCs of an unrelated donor 
(responder) at a stimulator:responder ratio of 1:1 in complete medium at a 
density of 0.75x106 cells/cm2. Cells were then incubated at 37⁰ C, 5% CO2 for 
5 days. 
 
NK cells were purified by positively selecting CD56+ cells from healthy donor 
PBMCs (Miltenyi Biotec Ltd) and activated with recombinant human-IL-2 
(1000 U/ml) (Peprotec EC Ltd). 
New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)-specific 
CD8+ T cell clone (Clone 4D8) was kindly supplied by Prof. Vincenzo 
Cerundolo (Institute of Molecular Medicine, Oxford university, UK). The clone 
was expanded in complete RPMI 1640 with Sodium Pyruvate (1 mM), 2-
Mercaptoethanol (0.05 mM) (ThermoFisher Scientific), recombinant human-




Mh CD8+ cells were stimulated using the following protocol: 5x106 purified Mh 
CD8+ cells were plated in 24-well plates in the presence of CD3/CD28-coated 
beads (Dynabeads®) (ThermoFisher Scientific) in a final volume of 2 ml of 
complete RPMI and incubated for 72 hours. 
 
2.8 Immunosuppressive assay 
 
Serial dilutions of human MSCs were plated in a flat bottom 96-well plate and 
let adhere overnight in 100 µl of complete RPMI. Where indicated, MSC 
cultures were exposed to human Interferon-γ (hIFNγ) and human TNF-α 
(hTNFα), murine IFN-γ (mIFNγ) and murine TNFα (mTNFα) (20 ng/ml each) 
(all cytokines were from Peprotec EC Ltd), supernatant from PHA-aPBMCs 
or from murine splenocytes (mSpl) activated with concanavalin A (ConA). 
Both supernatants were obtained from 72-hour stimulation of human PBMCs 
or mSpl with 5g/ml (PHA) or 3g/ml (ConA), respectively. 
The following day, 5x105 Balb/C mSpl were labelled with Carboxyfluorescein 
Diacetate Succinimidyl Ester dye (ThermoFisher Scientific) and plated with 
MSCs at escalating MSC:mSpl ratios. Culture controls consisted of mSpl 
plated without MSCs in the presence (positive control) or in the absence 
(negative control) of ConA (3g/ml). Proliferation of mSpl was then assessed 
by flow-cytometry after 72 hours and expressed as the percentage of the 
proliferation obtained at each MSC:mSpl dilution in comparison with the one 
obtained in the positive control culture. Results were expressed as 
percentage of inhibition. 
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2.9 Cytotoxic Assay 
 
1x105 MSCs were plated overnight in a total volume of 500 µl. The day after 
pre-activated immune cells were plated at different concentrations (2.5 to 40:1 
effector:MSC ratios). MSC apoptosis was then tested at different time points 
using flow-cytometry or confocal microscopy analysis. Eventually, the assay 
was performed for 4 hours in most of the cases. At flow-cytometry, MSCs 
were identified as CD45- cells. 
 
Antigen-specific cytotoxic activity of clone 4D8 was tested using T2 cells 
pulsed with NY-ESO-1 antigen (epitope SLLMWITQC) at a concentration of 
0.1 µM for 1 hour. In the competition assay, T2 (from Hans Stauss, University 
College London) and K562 cells (from Junia Melo, Imperial College London) 
were discriminated from effector cells by CellTrace Violet labelling. The tracer 
concentration was optimized for the T2 (1 µM) and K562 (2.5 µM) cells. Cell 
lines were tested for mycoplasma contamination before use. 
 
When flow-cytometry was used, the level of apoptosis was assessed using 
the PE annexin-V apoptosis detection kit (BD Biosciences). Unless specified, 








Cultures were supplemented with pan-caspase inhibitor Z-VAD-FMK (10 µM 
in the flow-cytometry experiments or 50 µM in the living cell confocal 
experiments) (R&D System), perforin inhibitor EGTA (4 mM) (Sigma-Aldrich 
Company Ltd), GrB inhibitor Z-AAD-CMK (300 µM) (Merk Millipore), 
AMD3100 (antagonist of CXCR4, for blockage of the CXCL12/CXCR4 axis) 
(25 µg/ml, and 250 µg/ml) (Sigma), neutralizing antibodies against HLA-DR 
(clone L243) (50 µg/ml), human HLA-A,B,C (clone W6/32) (100 µg/ml) (BD 
Biosciences), TNFα antagonist Etanercept (Enbrel®) (10 µg/ml or 100 µg/ml) 
(Amgen), CD18 (forming the β2 integrins lymphocyte function-associated 
antigen-1 and macrophage-1 antigen) (Clone TS1/18, 9 µg/ml and 90 µg/ml) 
(Biolegend), CD29 (Clone P5D2, 10 µg/ml and 100 µg/ml) (R & D Systems), 
CD44 (Clone Hermes-1, 10 µg/ml and 100 µg/ml) (Thermo Scientific), 
Intercellular Adhesion Molecule 1 (ICAM-1) (Clone R6.5, 50 µg/ml and 250 
µg/ml) (Affymetrix), ICAM-2 (Clone CBR-IC2/2, 50 µg/ml and 250 µg/ml) 
(eBioscience), vascular cell adhesion molecule 1 (VCAM-1) (Clone P3C4, 
100 µg/ml and 250 µg/ml) (Millipore), αvβ3 (Clone LM609, 50 µg/ml and 250 
µg/ml) (Millipore). Each reagent was incubated with MSCs 1 hour before the 
culture with effector killer cells. In all cases, the concentration of the 
corresponding inhibitor was kept for the duration of the cytotoxic assay. 
 
The neutralizing anti-CD178 (Clone NOK-1) (10 µg/ml or 100 µg/ml) (BD 
Biosciences), anti- TNF-related apoptosis-inducing ligand (TRAIL) (clone 
2E2) (10 µg/ml or 100 µg/ml) (Enzo Life Sciences) antibodies, MYR Protein 
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Kinase-Cζ Pseudosubstrate (PKCζ-PS) (10 µM, 25 µM or 75 µM) 
(ThermoFisher Scientific) and Etanercept (10 µg/ml or 100 µg/ml) were 
incubated with effector killer cells for 2 hours before the cultures with MSCs. 
In all cases, the concentration of the corresponding inhibitor was kept for the 




The following antibodies specific for murine molecules were used: anti-CD45 
(FITC, Clone 30-F11) (eBiosciences Ltd), anti-Vβ8.3 (FITC, Clone 1B3.3), 
anti-CD8 (APC, Clone 53-6.7), antiCD4 (PE, Clone H129.19), anti-CD19 
(APC-H7, Clone 1D3), anti-NK1.1 (PerCP-Cy5.5, Clone PK136) (BD 
Biosciences), anti-CD11b (PerCP-Cy5.5, clone M1/70), anti-CD11c (APC-
Cy7, clone n418), anti-Ido1 (Alexa Fluo647, clone 2e2) (BioLegend). For 
human specific molecules, the following antibodies were used: anti-CD45 
(FITC, clone 2D1), anti-CD8 (APC, Clone SK1), anti-CD4 (PE, Clone SK3), 
anti-CD11b (PerCP-Cy5.5, clone M1/70), anti-CD56 (FITC, clone HCD56) 
(BD Biosciences). 
 
All samples were acquired using BD FACS Canto II using the software FACS 
Diva and analysed with Flow-jo software. FRET and Caspase activity (CAf) 




2.12 Real Time quantitative PCR 
 
MSC RNA was obtained from TRIzol® (ThermoFisher Scientific) lysates and 
extracted using RNeasy Mini Kit (Qiagen). Real Time quantitative PCR (qRT-
PCR) was performed following TaqMan® RNA-to-CT 1-Step Kit instructions 
(ThermoFisher Scientific), using 20 ng of RNA template per reaction. Assays 
were carried out in duplicates on an StepOnePlus RT PCR system thermal 
cycler (Applied Biosystem) using TaqMan primers (all purchased from 
ThermoFisher Scientific). The human primers used were the following: IDO 
(Hs01589373_m1), TSG-6 (Hs01113602_m1) and Prostaglandin-
Endoperoxide Synthase 2 (PTSG2) (Hs00153133_m1) and hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) (Hs02800695_m1) as housekeeping 
gene. Data were then analysed using StepOne software version 2.1 and 
relative quantification obtained with ΔΔCt method, considering untreated 




Results were expressed as mean±SD. The unpaired Student t test was 
performed to compare 2 mean values. One-way ANOVA and Tukey’s Multiple 





In the analysis of the data obtained from the 32 patients with steroid resistant 
aGvHD used for the study of the cytotoxic assay, the following statistical 
methods were used: survival curves were given for MSC treated vs untreated 
patients as well as responders vs non-responders. Median survival times with 
95% confidence limits, as well as the p-value from the log rank test were given 
to compare survival curves. Demographic and treatment characteristics were 
compared using the t-test or Fisher’s exact test. R Version 3.3 and an alpha 
level of 0.05 were used for all analysis. 
 
The retrospective analysis of the cohort of 60 GvHD patients was performed 
as following: the associations of patient, disease and treatment factors with 
survival and disease response were investigated using the log-rank test, chi-
squared test or chi-squared trend test, respectively. Probabilities of survival 
were estimated using the Kaplan-Meier method. 
 
P-values less than 5% (p<.05, two-sided) was considered statistically 
significant. SPSS version 25 (IBM Corp. Released 2017. IBM SPSS Statistics 




3 MSC apoptosis after infusion is instrumental 
for immunosuppression and requires 




In the general introduction, we have described how MSCs exhibit potent 
immunosuppressive and anti-inflammatory activities. For these reasons, 
MSCs have received center stage attention and they have been extensively 
tested in several immune mediated diseases, including GvHD. Despite the 
very encouraging results, the extensive clinical use has been undeterred by 
the fact that the mechanisms underlying MSC therapeutic activity remain 
poorly understood. 
 
Two major unresolved challenges undermine the progress in the field. The 
first is that, only a proportion of patients, although affected by the same 
disease, responds to MSC infusions (Table 1.1) and this response cannot be 
predicted. The second is that the vast majority of infused MSCs become 
undetectable a few hours after transiently residing in the lungs2,131. Despite 
this, MSCs appear to maintain their ability to deliver therapeutic activities, and 
our current knowledge cannot provide an explanation to the paradox of the 
absence of engraftment and immunosuppressive functions42,59,132,381. 
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The most obvious explanation for the lack of MSC engraftment is that the cells 
die after infusion. Understanding whether this impairs or can in fact contribute 
to the immunosuppressive activity in vivo may provide crucial information to 
improve clinical efficacy and make therapeutic achievements more 
reproducible. By using a mouse model of aGvHD, we have tested the 






3.2.1 MSC undergo apoptosis in recipient GvHD animals. 
 
We utilized a mouse model of GvHD in which lethally irradiated C57BL/6 male 
mice were transplanted on day 0 with BM cells and polyclonal purified CD4+ 
T cells from female syngeneic donors and purified CD8+ T cells transgenic for 
a T-cell receptor specific for the mouse male HY-antigen Uty (Mh) as GvHD 
effectors373 (Figure 3.1). The addition of CD4+ T cells is necessary to facilitate 
the expansion of the CD8+ T cells. In this model, the expansion of the T cells 
effecting GvHD (CD8+Vβ8.3+) can be precisely enumerated and correlates 
with the clinical severity of the disease. 
 
In order to explain the mechanism by which MSC are rapidly cleared after 
injection2,131, we tested the hypothesis that MSC undergo in vivo apoptosis. 
Caspase activation was evaluated by using MSCs transfected with the pGL3 
Control Vector containing SV40 promoter and enhancer sequences for the 
expression of firefly luciferase (Luc+) (luc-MSC). Caspase activation was 
measured by luciferase activity using injection of Z-DEVD-aminoluciferin, a 
firefly luciferase pro-substrate containing the DEVD oligopeptide recognized 
by Caspase 3. Only upon activation of Caspase 3, DEVD can be cleaved, 
aminoluciferin released and eventually metabolized by the firefly luciferase 
expressed in MSCs. Luc-MSCs were injected into recipients of BM transplant 
with CD8+ Mh T cells (GvHD group) 3 days after the transplant. One hour 
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after infusion, caspase activity was measured in vivo as TLS. Two groups of 
control mice received MSCs. One consisted of untreated males (naïve group), 
and the second was a group of mice which were irradiated and received CD4+ 
T cells and BM cells (BM group) without the transgenic Mh CD8+ T cells. This 
latter group reproduces the condition of MSC infusion in the absence of 
activated cytotoxic GvHD effector T cells. Graphic representation of the 




Figure 3.1. Experimental design: GvHD mouse model and Caspase 3 




Figure 3.1. Experimental design: GvHD mouse model and Caspase 3 
activation study in MSCs Untreated (naïve) or lethally irradiated C57BL/6 
male mice were transplanted with bone marrow (BM) and CD4+-purified cells 
from female syngeneic donors with or without CD8+ cells purified from Mh 
mice (CD8+Vβ8.3+) (GvHD and BM groups, respectively). At day +3 post-
transplant, luc-MSCs were infused. One hour after infusion, mice were first 
anesthetised with Isoflurane, then injected intraperitoneally with Z-DEVD-
Amoniluciferin and imaged in an IVIS Lumina Caliper chamber for 5 minutes. 
At day +7 post-transplant, mice were sacrificed and the infiltration of GvHD 




High caspase activity, measured as TLS, was observed only in the GvHD 
group (mean TLS: 26.52 [SD: 12.31, 95% CI: 13.60-39.43]), while significantly 
lower caspase activity could be found in mice of both BM and naïve groups 
(mean TLS were 6.13 [SD: 6.72, 95% CI: -0.92-13.19] and 1.86% [SD: 2.98, 
95% CI: -1.26-4.99], respectively) (Figure 3.2A and B). 
To confirm that luc-MSCs could be tracked in the lungs of all animals, 
including those with low or absent caspase activity, we subsequently infused 
mice with the control D-luciferin (firefly luciferase substrate). We could find 
that high signal could be detected from all animals (Figure 3.2C), with not 
significant difference among groups. Mean TLS were 29.10 (SD: 13.18, 95% 
CI: 15.26-42.94), 27.13 (SD: 25.29, 95% CI: 0.594-53.67), and 28 (SD: 6.91, 








Figure 3.2. MSCs undergo apoptosis in vivo after infusion. A: luc-MSCs 
were injected i.v. into naïve, BM and GvHD mice 3 days after transplantation. 
All animals were then injected i.p. with DEVD-aminoluciferin and imaged 1 
hour later. N: total of 6 (1 to 3 mice per group), grouped from 3 independent 
experiments. In each experiment, a different MSC expansion was used. White 
lines separate multiple photographs assembled in the final image. B: Total 
luminescence signal (TLS) was measured from the images of mice in Figure 
4A and shown as mean±SD. C: in order to confirm the presence of luc-MSC 
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in the lungs of all groups of mice infused with MSCs, the same mice imaged 
in Figure 4A were injected with D-Luciferin. White lines separate multiple 
photographs assembled in the final image. D: Total luminescence signal 
(TLS) was measured from the images of mice in C and shown as mean±SD. 
Statistics in B and D: one-way ANOVA, with Tukey’s Multiple Comparison 
Test. **: p<.01, ***: p<.001, ns: not significant.
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The evidence that MSCs undergo apoptosis after infusion prompted the 
question of whether they were still capable of suppressing antigen-driven T 
cell expansion. Therefore, we analyzed their immunosuppressive effect by 
enumerating CD8+Vβ8.3+ Mh T cells (GvHD effector cells) in MSC-treated or 
untreated GvHD mice. MSCs produced a substantial reduction in GvHD 
effector cell infiltration in both spleen and lungs in comparison with untreated 
mice (Figure 3.3A-C). Mean percentage of GvHD effector cells was 17.87% 
(SD: 6.933, 95% CI: 14.03-21.71) and 8.83 (SD: 4.34, 95% CI: 6.20-11.45) in 
the spleen of untreated or MSC-treated GvHD mice, respectively (Figure 
3.3B). Similar results were obtained in lungs, whereby the mean percentage 
of infiltrating GvHD cells was 19.76% (SD: 6.31, 95% CI: 16.26-23.25) and 
12.12 (SD: 2.32, 95% CI: 10.71-13.52) in GvHD and GvHD-MSC mice, 
respectively (Figure 3.3C). These results indicate that, despite the presence 




Figure 3.3. MSCs prevent in vivo expansion of GvHD-effector cells in 




Figure 3.3. MSCs prevent in vivo expansion of GvHD-effector cells in 
our pre-clinical model of aGvHD. A: Percentage of GvHD effector cells 
(CD8+Vβ8.3+) calculated in the lymphocyte gate (defined by the physical 
characteristics of the cells) in treated (GvHD+MSC) and untreated (GvHD) 
mice, evaluated 4 days after MSC injection by flow cytometry. Representative 
dot plot. B-C: Infiltration of GvHD effector cells assessed as described in A in 
the spleen (B) and lungs (C) of GvHD mice (black circles) and GvHD mice 
treated with MSC (black squares). N: 15 (GvHD) and 13 (GvHD+MSC) mice, 
grouped from 4 independent experiments; mean±SD are shown. Statistics: 
unpaired t-test. **: p<.01.
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In our model, we could reasonably exclude the possibility that MSC 
immunosuppressive activity were the consequence of MSC being exposed to 
the recipient inflammatory cytokines because in our xenogeneic combination 
murine inflammatory cytokines do not cross-react with the corresponding 
human receptors and will not activate immunosuppressive molecules in 
human MSCs43,82,382, whilst retaining the ability to expand murine effector 
cells mediating GvHD383. Accordingly, human MSCs were not able to inhibit 
ConA induced proliferation of mSpl unless pre-activated by human cytokines 
(Figure 3.4A-C). Furthermore, exposure of human MSCs to murine 
inflammatory cytokines did not upregulate IDO, TSG-6, or PTSG2 (enzyme 
involved in the production of PDGE2), considered major effectors of human 
MSC-mediated in vitro immunosuppression (Figure 3.4D).
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Figure 3.4. Human MSC immunosuppression is not ‘licensed’ by murine 
cytokines. A: Human MSCs were plated overnight at serial dilutions alone or 
with ConA-activated murine Spl supernatant, PHA-activated human PBMC 
supernatant, murine IFN-γ/TNF-α (20 ng/ml each) or human IFN-γ/human 
TNF-α (20 ng/ml each) as indicated. MSCs were then tested for the ability to 
inhibit ConA-induced splenocytes proliferation for 72 hours. Proliferation was 
determined by carboxyfluorescein succinimidyl ester staining. The 
percentage of inhibition was calculated subtracting the percentage of 
proliferation to 100 and then plotting against the corresponding MSC/Spl ratio. 
B: human MSCs were plated overnight either untreated or exposed to 
hIFNγ/hTNFα (20 ng/ml each) as indicated and then tested for the ability to 
suppress mSpl proliferation at 1:10 MSC/Spl ratio. Representative histogram 
plot. C: human MSCs were plated as in B. Results of 3 independent 
experiments are shown. D: human MSCs were incubated for 24 hours with 
PHA-stimulated human PBMC or ConA-stimulated murine Spl (separated by 
a transwell), mIFN-γ/mTNF-α (20 ng/ml each) or hIFN-γ/hTNF-α (20 ng/ml 
each) as indicated. IDO, TSG-6, and PTSG2 expression were then assessed 
by real time PCR and calculated as relative expression in comparison to that 
of untreated MSCs. Representative results of three independent experiments 
are shown. Statistics: One-way ANOVA and Tukey’s Multiple Comparison 
test. ***: p<.001. MSC: Mesenchymal Stromal Cells, ConA: Concanavalin-A, 
Spl: splenocytes, PHA: phytohemagglutinin, PBMC: Peripheral Blood 
Mononuclear Cells, IFN-γ: Interferon-γ, TNF-α: Tumour Necrosis Factor-α.
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3.2.2 In vivo MSC apoptosis depends on activated recipient 
GvHD effector cells. 
 
Our results show that MSCs rapidly undergo apoptosis after infusion, 
providing an explanation for the rapid clearance of transplanted MSCs in the 
recipient2,131. The absence of in vivo MSC apoptosis in naïve mice clearly 
demonstrates that MSC apoptosis is not the result of xenogeneic recognition 
of human MSCs. Furthermore, our results suggest that caspase 3 activation 
in MSCs is associated with the presence of cytotoxic cells, since MSC 
apoptosis could be detected only in GvHD but not in BM mice (mice not 
receiving GvHD effector cells in their transplant) (Figure 3.2A and B). 
To better evaluate this relationship, we first enumerated GvHD effector cell 
infiltrate (CD8+Vβ8.3+) in the lungs of mice, where MSC apoptosis occurs in 
all groups. We found that only the lungs of GvHD, but not naïve and BM mice, 
contained a large proportion of CD8+Vβ8.3+ cells (Figure 3.5A), thus 
confirming the correlation between caspase activation in MSCs and the 
presence of GvHD effector cells. Percentage of CD8+Vβ8.3+ cells in lungs was 
0.01% (SD: 0.03, 95% CI: 0.01-0.17), 0.59% (SD: 0.76, 95% CI: -1.29-2.48), 
and 14.22% (SD: 3.75, 95% CI: 11.83-16.60) in naïve, BM, and GvHD mice, 
respectively.  
To test the hypothesis that GvHD effector cells were responsible for MSC 
apoptosis, MSCs were cultivated with CD8+ T cells purified from the lungs or 
spleens of GvHD (in vivo activated) or naïve Mh (in vivo resting) mice. 
Activated, but not resting, Mh CD8+ T cells induced MSC apoptosis (Figure 
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3.5B). Indeed, percentage of annexin V+/7-AAD- cells were 19.37% (SD: 0.35, 
95% CI: 18.49-20.24) in MSCs when in co-culture with CD8+ T-cells from 
lungs obtained from naïve mice and 30.63% (SD: 5.88, 95% CI: 16.02-45.25) 
in MSCs when in co-culture with CD8+ T-cells from lungs obtained from GvHD 
mice. Similarly, apoptotic MSCs were 11.95% (SD: 0.63, 95% CI: 6.23-17.67) 
when in co-culture with CD8+ T-cells from spleens obtained from naïve mice, 
while they were 22.17% (SD: 2.31, 95% CI: 16.42-27.91) in MSCs when in 
co-culture with CD8+ T-cells from spleens obtained from GvHD. Background 
level of annexin V+/7-AAD- cells in MSCs cultured alone were 11.45% (SD: 
4.71, 95% CI: 6.50-16.40) (Figure 3.5B). Similar proportion of cytotoxicity 
against MSCs could be elicited by naïve Mh CD8+ T cells when stimulated in 
vitro by CD3/CD28 beads (Figure 3.5C). Annexin V+ cells were 11.13% (SD: 
0.83, 95% CI: 3.63-18.63) and 39.20% (SD: 0.84, 95% CI: 31.58-46.82) in 
MSCs alone and MSCs in co-culture with CD3/CD28 activated CD8+ T-cells, 
respectively. 
 
Taken together, these data show the association between the presence of 




Figure 3.5. MSC apoptosis is associated with the presence of activated 
GvHD effector cells. 
 
 
Figure 3.5. MSC apoptosis is associated with the presence of activated 
GvHD effector cells. A: The percentage of CD8+Vβ8.3+ cells in lung cell 
suspensions from naïve C57BL/6 male, BM or GvHD mice was analyzed in 
the lymphocyte population; mean±SD are shown. N: 12 (GvHD), 3 (BM) and 
3 (naïve) mice, grouped from 3 independent experiments. B: CD8+ cells were 
sorted from the lungs and spleens of naïve female Mh (grey bars) or GvHD 
mice (not treated with MSC) (white bars) 7 days after the transplant and 
tested for their ability to induce MSC apoptosis in vitro. The results show 
annexin-V+/7-AAD- MSC (mean±SD) in 3 independent experiments (N=10 
per group), black bar represents the value of apoptosis in MSCs cultured 
alone used as control (N: 3). C: CD8+ T cells isolated from naïve female Mh 
mice were stimulated for 3 days with anti-CD3/CD28 beads and cultured with 
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MSCs at a 20:1 Mh T-cell:MSC ratio. After 4 hours apoptosis was assessed 
in MSC by annexin-V/7AAD staining. Results represent the mean±SD of 3 
independent experiments. Statistics: One-way ANOVA, with Tukey’s Multiple 
Comparison Test. *: p<.05; ***: p<.001.
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The requirement of cytotoxic cells in the induction of MSC apoptosis was 
further evaluated using Mh/Perforin Knock-Out mice (Mh/Perf-/-) as donors of 
defective cytotoxic GvHD effector cells (GvHDPerf-/- group). 
 
Luc-MSCs were infused into GvHDPerf-/- or control GvHD mice which had 
received Mh CD8+ T cells. Mice were imaged 1 hour later, and caspase 
activation measured as described above. We confirmed that high signal of 
apoptosis could be observed in the GvHD group (26.07 [SD: 7.40, 95% CI: 
19.23-32.92]). However, significantly lower caspase activity could be found in 
GvHDPerf-/- mice (6.16 [SD: 5.63, 95% CI: 0.95-11.36]) (Figure 3.6A-B). 
 
To assess that the signal detected in lungs of GvHDPerf-/- mice was not 
dependent on a defective activity of the luciferase vector in MSCs, both 
groups of mice were eventually imaged using the control D-luciferin. Similar 
emission patterns were found in both groups, thus confirming that when 
MSCs were infused into GvHDPerf-/-, caspase 3 was not activated (Figure 
3.6C-D). 
 
We could conclude that MSC apoptosis in vivo requires the presence of 
functional cytotoxic GvHD effector cells.
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Figure 3.6. GvHD effector cells are required to induce MSC apoptosis in 
vivo. A: luc-MSC were infused in two independent experiments in GvHD 
(N=7) and GvHDPerf-/- (N=7) mice 3 days after transplantation. 1 hour later 
mice were injected with Z-DEVD-aminoluciferin and imaged. White lines 
separate multiple photographs assembled in the final image. B: TLS was 
obtained from Figure 8A and expressed as mean±SD. C: In order to confirm 
the presence of luc-MSC in the lungs of all groups of mice infused with MSCs, 
the same mice imaged in Figure 2C were injected with D-Luciferin. White lines 
separate multiple photographs assembled in the final image. D: TLS was 
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measured from the images of mice in Fig. S3B and shown as mean±SD. 
Statistics: unpaired t-test. ***: p<.001. ns: not significant.
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We then evaluated the immunosuppressive activity of MSCs in the absence 
of apoptosis induction. The infiltration of GvHD effector cells in the spleen and 
lungs of mice receiving MSCs was not reduced in GvHDPerf-/- (Figure 3.7A 
and B). In details, mean percentage of GvHD effector cells was 11.92% (SD: 
9.78%, 95% CI: 6.71-17.13) and 12.32% (SD: 8.20%, 95% CI: 8.10-16.53) in 
the spleen of GvHDPerf-/- in the absence or presence of MSC treatment, 
respectively. Similarly, GvHD effector cell infiltration was 27.92% (SD: 15.55, 
95% CI: 9.92-35.91) and 22.17% (SD: 10.55, 95% CI: 16.55-27.79) in lungs 
of treated or untreated animals, respectively (Figure 3.7B). 
 
We conclude that MSC apoptosis is indispensable for immunosuppression 
and requires functionally activated cytotoxic cells in the recipient.
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Figure 3.7. MSC immunosuppression is abrogated in the absence of 
cytotoxic cells. A-B: The percentage of effector GvHD cells (CD8+Vβ8.3+) in 
the lymphocyte population was measured in the spleen (A) and lungs (B) of 
untreated GvHDPerf-/- (N=16) and GvHDPerf-/- (N=17) mice treated with MSC 




3.2.3 Cytotoxic activity against MSCs is associated with 
clinical response to MSCs in GvHD patients. 
 
Based on these findings, we inferred that the presence of cytotoxic cells in 
the recipient could be predictive of clinical responses to MSCs. We collected 
PBMCs from 32 patients affected by steroid-resistant aGvHD who were 
candidate to receive MSCs. Patient characteristics are summarized in Table 
3.1. Twenty (62.5%) patients were treated in the UK, while the remaining were 
enrolled in Germany. Median age was 49 years (range: 3-69), 27 (87%) were 
males. All patients were transplanted because of a malignancy. 
 
Fourteen patients (45%) received a transplant from a sibling, 12 (39%) from 
an unrelated donor, 3 (10%) from a haploidentical donor, and in 2 (6%) HSCs 
were obtained from cord blood. Twenty-four (77%) had a myeloablative 
conditioning regimen, while in the remaining 7 (23%) a reduced intensity 
regimen was used.  
 
GvHD prophylaxis mostly comprised cyclosporine A (CSA) alone or in 
combination with methotrexate (MTX) or Mycophenolate (MMF). In 26 (81%) 
patients MSCs were used after at least two previous treatments, while only in 
3 patients (9%) MSCs were used as second line after failure of steroids (2 




Skin, gut, and liver were affected in 14 (43.8%), 26 (81.2%), and 6 (18.8%) of 
the patients. Most patients had multiorgan GvHD, while only in two (6.3%), 
12 (37.5%), and 1 (3.1%) patients, skin, gut or liver were the only organs 
affected, respectively. 
 
Median time from HSCT or GvHD diagnosis to MSC treatment was 92 (33-
564) or 23 (4-163) days, respectively. Median dose of MSCs was 1.2x106/Kg 
body weight (range 0.7-7.4). Response to MSC treatment was assessed as 
described in Material and Methods. After 33 infusions, responses were 
observed in thirteen cases (39.4%), in all cases a partial response was 
reported. When we studied the distribution of responses in the patients 
treated in the UK and in Germany, we could find that in the former group of 
patients, partial response was achieved in 11 out of 20 patients (55%), while 
in the latter only 2 out of 12 patients (17%) were partial responders (Figure 
3.8). In all patients, MSC infusions were well tolerated.
125 
 
Figure 3.8. Distribution of clinical responses amongst patients treated 
in the UK and Germany. 
 
 
Figure 3.8. Distribution of clinical responses amongst patients treated 
in the UK and Germany. Distribution of responders and non-responders in 
patients who were treated in the UK or in Germany.
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Table 3.1. Patients’ characteristics. 
 
Total (n) 31 
Age, years              









NHL/HL/MM/Other malignancies 10 
Time from HSCT to MSC treatment  
Median (range, days) 92 (33-406) 
Time from GvHD to MSC treatment  
Median (range, days) 23 (4-163) 
Type of transplant*  
Sibling 14 
Unrelated 11 
Umbilical cord 2 
Haploidentical 3 
Conditioning Regimen*  
Myeloablative 24 
Reduced Intensity 6 




Other drugs 7 
GvHD treatment before MSC infusion**, n   
Methylprednisolone Alone 2 
Methylprednisolone in combination with other drugs 26 
Other drug combination not including Methylprednisolone 1 
CSA 15 
MMF 10 






anti-CD52 (Alemtuzumab) 3 
ATG 1 
JAK1/2 Inhibitors (Ruxolitinib) 5 
Imatinib  2 
Budesonide 3 
GvHD grade, n  
I-II 2 
III-IV 28 





aGvHD: acute Graft versus Host disease, AML: Acute Myeloid Leukemia, 
ALL: Acute Lymphoblastic Leukemia, ATG: anti-thymocyte globulin, CML: 
Chronic Myeloid Leukemia, CSA: Cyclosporin, ECP: Extracorporeal 
photopheresis, , JAK1/2: Janus kinase 1/2, HSCT: Hematopoietic Stem Cell 
Transplant, MEP: Methylprednisolone, MDS/MPNs: Myelodisplastic 
Syndrome/Myeloproliferative Neoplasms, MMF: Mycophenolate, MSC: 
Mesenchymal Stromal Cells, MTX: Methotrexate, NHL/HL/MM: Non-Hodgkin 
Lymphoma/Hodgkin Lymphoma/Multiple Myeloma, TNFα: Tumor Necrosis 
Factor α. 
*: Information was not reported for two patients. **: Information was not 
reported for three patients.
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PBMCs were freshly collected within the 24 hours preceding the MSC infusion 
and tested directly for their ability to induce MSC apoptosis ex vivo in a 4-
hour cytotoxic assay. One patient received two doses of MSCs, and the 
cytotoxic assay was performed before each dose independently. In 8 assays 
the MSCs were sourced from the same donor used for the infusion, while in 
the remaining they were obtained from a different donor. At the time of 
performing the assay and cytofluorimetric analysis the operator was blind to 
patients’ clinical details. PBMCs from healthy donors (N=5) were used as 
controls. 
 
Overall, PBMCs from GvHD patients exhibited a higher cytotoxicity against 
MSCs in comparison with that observed when PBMCs from healthy donors 
were used. Mean percentage of annexin V+/7AAD- MSCs was 12,36% (SD: 
12.07, 95% CI: 8.08-16.64) and 3.82% (SD: 2.50, 95% CI: 0.72-6.93) when 
MSCs were in co-culture with PBMCs obtained from GvHD patients or healthy 
controls (HC), respectively (p=0.04). However, the cytotoxicity was broadly 
variable, ranging from 0% to 62.3%. We then divided patients into two sub-
categories according to MSC response (responders and non-responders), 
and analyzed the distribution of the results of the cytotoxic assay among 
them. We found that cytotoxicity was markedly higher when PBMCs were 
isolated from clinical responders in comparison with non-responders or 
healthy controls. Indeed, when MSCs were in co-culture with PBMCs from 
responding patients the mean proportion of annexin V+/7AAD- MSCs was 
19.64% (SD: 15.16, 95% CI: 10.01-29.28), three-fold higher than what 
observed with PBMCs from non-responders (6.90, SD: 4.75, 95% CI: 4.68-
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9.13), and five-fold higher than PBMCs from healthy controls (3.82, SD: 2.50, 
95% CI: 0.72-6.93) (Figure 3.9A-B). 
 
Importantly, when we analysed the ability of our cytotoxic assay to 
discriminate between responders and non-responders by using the receiver-
operating characteristic curve, we found that, when setting a threshold of 
apoptotic MSCs at 11.55%, this cut-off was predictive of clinical response with 
85% sensitivity (95% CI: 54.55% to 98.08%) and 90% specificity (95% CI: 
68.3% to 98.77%) (Figure 3.9C).
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Figure 3.9. Cytotoxic activity against MSCs predicts clinical responses 




Figure 3.9. Cytotoxic activity against MSCs predicts clinical responses 
to MSCs in GvHD patients. A, B: PBMCs obtained from healthy controls 
(HC) or patients with GvHD receiving MSCs in the following 24 hours were 
incubated in 24-well plates with MSC at a 20:1 PBMC:MSC ratio for 4 hours. 
Apoptosis was measured in MSCs assessing the percentage of annexin-V+/7-
AAD- cells by flow-cytometry. A: Representative plots for HC, clinical 
responders (R) and non-responders (NR). The panels on the left show the 
background apoptosis of MSC alone used in the corresponding cytotoxic 
assay. B: Apoptosis was compared among HC (circles, N=5), NR (squares; 
N=20), and R (triangles; N=12). Statistics: one-way ANOVA and Tukey’s 
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Multiple Comparison test. **: p<.005, ***: p<.001 ns: not significant. C: 
Receiver-operating characteristic curve (ROC) was performed to assess 
specificity and sensibility of the functional assay to predict the clinical 
outcome of patients treated with MSCs. HC: Healthy Controls. NR: Non-
Responders. R: Responders 
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We then evaluated all possible factors that could affect the response to MSC 
treatment. We included in our analysis also the results of the cytotoxic assay, 
using the cut-off of 11.55%, and dividing our patients into two subgroups: 
cytohigh patients (with cytotoxicity >11.55%) and cytolow (with cytotoxicity 
<11.55%). Notably, the only factor significantly associated with response to 
MSCs was the cytotoxicity against MSCs (Table 3.2). Conversely, age at 
transplant, HSC source, conditioning regimen, time from HSCT to MSCs, time 
from GvHD to MSCs, treatment before MSCs, GvHD prophylaxis, MSC dose, 
or blood count did not have any impact on patient responses (Table 3.2).
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Table 3.2. Demographic and treatment characteristics for responders 
and non-responders. 
 
  Category NR (n=19) PR (n=13) 
p-
value 
Age (mean (sd))   49.56 (14.03) 37.75 (23.09) 0.092 
Transplant type (%) Sibling 6 (33.3) 8 (66.7) 0.25 
  Unrelated 9 (50.0) 2 (16.7)   
  Umbilical 1 (5.6) 1 (8.3)   
  Haplo 2 (11.1) 1 (8.3)   
Transplant intensity (%) 
Myeloablativ
e 
14 (77.8) 10 (83.3) 1 
  RIC 4 (22.2) 2 (16.7)   








MSC to GvHD (mean 
(sd)) 
  29.29 (40.72) 38.82 (34.10) 0.539 
Treatment before MSC         
Methylprednisolone (%) No 1 (5.6) 0 (0.0) 1 
  Yes 17 (94.4) 11 (100.0)   
CSA (%) No 8 (44.4) 6 (54.5) 0.71 
  Yes 10 (55.6) 5 (45.5)   
MTX (%) No 17 (94.4) 11 (100.0) 1 
  Yes 1 (5.6) 0 (0.0)   
MMF (%) No 12 (66.7) 7 (63.6) 1 
  Yes 6 (33.3) 4 (36.4)   
Anti TNFa (%) No 9 (50.0) 8 (72.7) 0.273 
  Yes 9 (50.0) 3 (27.3)   
Budeboside (%) No 16 (88.9) 10 (90.9) 1 
  Yes 2 (11.1) 1 (9.1)   
ECP (%) No 16 (88.9) 9 (81.8) 0.622 
  Yes 2 (11.1) 2 (18.2)   
Imanitib (%) No 17 (94.4) 10 (90.9) 1 
  Yes 1 (5.6) 1 (9.1)   
Tacrolimus (%) No 16 (88.9) 9 (81.8) 0.622 
  Yes 2 (11.1) 2 (18.2)   
Roxolitinib (%) No 14 (77.8) 10 (90.9) 0.622 
  Yes 4 (22.2) 1 (9.1)   
ATG (%) No 17 (94.4) 11 (100.0) 1 
  Yes 1 (5.6) 0 (0.0)   
Anti CD52 (%) No 16 (88.9) 10 (90.9) 1 
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ATG: anti-thymocyte globulin, CSA: Cyclosporin, ECP: Extracorporeal 
photopheresis, JAK1/2: Janus kinase 1/2, MEP: Methylprednisolone, MMF: 
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Mycophenolate, MSC: Mesenchymal Stromal Cells, MTX: Methotrexate, 
TNFα: Tumor Necrosis Factor α.
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An important question related to the cytotoxic assay is whether the results 
obtained could be dependent on the specific MSC donor or batch used to 
perform the assay. To address this important issue, we tested patients’ 
PBMCs against the MSCs used for the infusion and compared the results of 
the assay with those obtained by using another MSC preparation isolated 
from a different and unrelated donor. In this experiment MSC1 and MSC2 
were infused into patient 1 and patient 2, respectively. We found that when 
PBMCs obtained from patient 1 were used in our cytotoxic assay, the level of 
annexin V+/7AAD- cells were similar in MSC1 (14,2%) and in MSC2 (13,2%). 
Similarly, when PBMCs from patient 2 were employed, the levels of apoptosis 
in both MSCs was almost identical (MSC1: 21.1%, MSC2: 20.9%) (Figure 
3.10A). Taken together, our findings strongly support the notion that 
cytotoxicity did not vary amongst MSC preparations. 
 
To further confirm the dispensable role of the specific MSC batch in the 
cytotoxic assay, we evaluated the susceptibility of MSCs sourced from 
different unrelated donors to undergo apoptosis after exposure to 4 different 
mixed lymphocyte reaction (MLR) combinations. We decided to use PBMCs 
from a MLR because it is considered an in vitro surrogate of alloreactivity and 
GvHD384, thus closely recapitulating the use of PBMCs activated in vivo 
during GvHD. 
 
The proportion of apoptotic MSCs was similar amongst the different MSC 
preparations when the same MLR was tested. This similarity was confirmed 
by the study of the coefficients of variation calculated using the values of MSC 
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apoptosis obtained with each MLR. Conversely, the cytotoxic activity against 
the same MSCs varied amongst different MLR (Table 3.3 and Figure 3.10B).
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Table 3.3. Level of MSC apoptosis depends on specific MLR 
preparations. 
 
  MLR1 MLR2 MLR3 MLR4 
Mean level of MSC apoptosis 49 48.33 34.3 16.4 
Std. Deviation 2.326 4.562 2.404 1.556 
Std. Error of Mean 1.343 2.634 1.7 1.1 
Lower 95% CI of mean 43.22 37 12.7 2.423 
Upper 95% CI of mean 54.78 59.67 55.9 30.38 
Coefficient of variation 4.75% 9.44% 7.01% 9.49% 
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Figure 3.10. Cytotoxicity against MSCs varies amongst PBMC donor. 
 
 
Figure 3.10. Cytotoxicity against MSCs varies amongst PBMC donor. A: 
PBMCs obtained from 2 different GvHD patients (Patient 1 and Patient 2) 
were tested for their cytotoxic activity against MSCs from two different donors 
(MSC1 and MSC2). MSC1 and MSC2 were infused into patient 1 and patient 
2, respectively. B: apoptosis in MSCs obtained from different donors (MSC1, 
MSC2 and MSC3) after incubation with PBMCs from four different MLR 
responder/stimulator combinations (MLR1, MLR2, MLR3, MLR4). In A and B, 




We have shown that responders and non-responders exhibited different 
cytotoxicity against MSCs (Figure 3.9A-B). We then studied the frequency of 
CD8+ cells and NK cells (CD56+) in both categories of patients, and we could 
rule out the possibility that different proportions of these cells could account 
for the observed difference in cytotoxic activity. Indeed, the average 
frequency of CD8+ in the PBMCs of responders (2.83%, SD: 0.68, 95% CI: 
1.99-3.68) was not different from the frequency of these cells in non-
responders (3.40, SD: 3.00, 95% CI: 1.25-5.55) (Figure 3.11A). Similar results 
were obtained when the frequency of NK cells was considered in both 
category of patients. CD56+ cells were 15.25% (SD: 11.1, 95% CI: 1.47-
29.03) in responders, and 11.33% (SD: 8.83, 95% CI: 5.01-17.64) in non-
responders (Figure 3.11B). Therefore, we conclude that the presence of 




Figure 3.11. Cytotoxicity against MSCs is independent of the percentage 




Figure 3.11. Cytotoxicity against MSCs is independent of the percentage 
of CD8+ or CD56+ in GvHD patients. A, B: PBMCs obtained from 11 GvHD 
patients (R: 3, NR: 8) were analysed for the percentage of CD8+ (A) and 




3.2.4 MSC apoptosis induced by cytotoxic cells is the result 
of a bystander effect. 
 
To define the mechanisms that drive apoptosis in MSCs, we used in-vitro-
activated PBMCs from healthy donors as effector cells. PBMCs were pre-
activated incubating them with PHA (5 µg/ml) for 72 hours, or in a MLR for 5 
days. MSCs were then plated in 24 well plate alone, or in co-culture with PHA 
or MLR pre-activated PBMCs at different PBMC:MSC ratios (2.5/1 to 40/1). 
The level of apoptosis within MSCs was then assessed by Annexin V/7-AAD 
staining using flow-cytometry at different time points (30 minutes to 24 hours). 
We found that activated but not resting PBMCs induced extensive early 
apoptosis (annexin-V+/7AAD-) in MSCs (Figure 3.12A). This apoptosis 
peaked at 4 hours reaching a plateau at a PBMC:MSC ratio 20/1 (mean 
84.27%, SD: 3.3, 95% CI: 76.15-92.38) and shifted towards late apoptosis 
(annexin-V+/7AAD+) by 24 hours (Figure 3.12B). When PBMCs activated with 
MLR were used, a plateau was reached at a PBMC:MSC ratio 20/1, and the 




Figure 3.12. MSC apoptosis is induced within the first 4 hours when in 




Figure 3.12. MSC apoptosis is induced within the first 4 hours when in 
contact with activated PBMCs. A: PBMCs from healthy donors (each 
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independent experiment used a different PBMC donor) were activated using 
PHA (PHA-aPBMC) or MLR (MLR-aPBMC). Resting (grey bars), PHA-
aPBMCs (black bars) or MLR-aPBMCs (dashed bars) were incubated with 
MSCs at the indicated ratios and MSC apoptosis (annexin-V+/7-AAD-) 
calculated after 4 hours. ND: Not done. B: PHA-aPBMCs were incubated with 
MSCs at escalating PBMC:MSC ratios. MSC apoptosis was assessed by 
annexin-V/7-AAD at different time-points by flow-cytometry. Results 
represent the mean±SD of 3 independent experiments with PHA-aPBMCs 
and 2 independent experiments when MLR-aPBMCs were employed. 
Statistics: one-way ANOVA, with Tukey’s Multiple Comparison Test. ****: 
p<.0001. ns: not significant.
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In order to confirm that annexin V expression in MSCs exposed to activated 
PBMCs was the result of caspase activation, MSCs were transfected with the 
pECFP-DEVDR-Venus vector. EC-RP construct is composed of a FRET 
donor-acceptor pair ECFP and venus (YFP) connected via a flexible linker 
containing the caspase cleavage sequence DEVDR380. In this system, in the 
absence of caspase 3 activity, the linker is intact, and energy can be 
transferred between the two fluorochromes. Such a condition translates in 
reduction of the signal of the donor fluorochrome (ECFP) and increase of that 
of the acceptor (YFP). Conversely, when the linker is cleaved in the presence 
of caspase 3 activation, energy transfer is lost, and ECFP and YFP signals 
result increased and reduced, respectively. Our data demonstrated that 
caspase 3 is indeed activated in MSCs and, in accord with our in vivo 
observations (Figure 3.2A and B), this activation could be induced only by 
activated PBMCs with a peak at 90 minutes (Video 3.1, 3.2 and 3.3). 
 
The crucial role played by caspase 3 was confirmed by the observation that 
MSC apoptosis was completely abrogated by the pan-caspase inhibitor Z-
VAD-FMK (Figure 3.13A and B, and Video 3.4). Indeed, annexin V+/7-AAD- 
MSCs were 46.20% (SD: 4.68, 95% CI: 35.57-58.83), 42.97% (SD: 9.05, 95% 
CI: 20.46-65.47) and 7.09% (SD: 0.12, 95% CI: 6.78-7.39) when MSCs were 
in co-culture with activated PBMCs, activated PBMCs and vehicle, or 
activated PBMCs and Z-VAD-FMK, respectively (Figure 3.13A). As expected, 
these data were confirmed when caspase 3 activation was evaluated using 








Figure 3.13. MSC apoptosis is caspase 3 dependent. A: Apoptosis in MSC 
cultivated with MLR-aPBMC at a PBMC:MSC ratio 20:1 in the presence or 
absence of the pan-caspase inhibitor Z-VAD-FMK (10 µM) or the 
corresponding concentration of its vehicle (DMSO). B: MSCs were 
transfected with the pECFP-DEVDR-Venus vector (FRET-MSC) and FRET 
between pECFP and Venus-YFP FRET was studied by flow-cytometry and 
Caspase activity (CAf) calculated as described in Materials and Methods380. 
FRET-MSCs were cultured alone, with PHA-aPBMCs, or PHA-aPBMCs in 
the presence of Z-VAD-FMK (50 µM). The PHA-aPBMC:MSC ratio was 40/1. 
Results represents the mean±SD of 3 independent experiments. Statistics: 




In order to identify the cells inducing apoptosis in MSCs, we performed 
selective enrichment and depletion experiments amongst activated PBMCs. 
CD56+ or CD8+ cells positively selected from MLR-aPBMCs were able to 
induce apoptosis in 38.9% (SD: 18.5, 95% CI: 23.41-54.39) and 21.6% (SD: 
3.9, 95% CI: 15.33-27.87) of MSCs in co-culture, levels which were similar to 
those obtained when unfractionated MLR-aPBMCs were used (35.9%, SD: 
14.7, 95% CI: 20.49-51.31). Conversely, when CD11b+ or CD4+ cells were 
selected, significantly reduced levels of MSC apoptosis was observed (Figure 
13.14A). Importantly, only when both CD8+ and CD56+ cells were depleted 
from MLR-aPBMCs, the induction of MSC apoptosis could be significantly 
reduced. Annexin V+/7-AAD- MSCs were 12.0% (SD: 4.54, 95% CI: 0.73-
23.29) when in co-culture with MLR-aPBMCs depleted of CD8+/CD56+, in 
contrast, when unfractionated PBMC were used, MSC apoptosis was 35.9% 
(SD: 14.68, 95% CI: 20.49-51.31) (Figure 3.14B). Taken together, these 
results demonstrate that both CD56+ natural killer (NK) and CD8+ T cell 
populations were the only cells responsible for initiating MSC apoptosis.
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Figure 3.14. Activated CD56+ and CD8+ cells are the only populations 




Figure 3.14. Activated CD56+ and CD8+ cells are the only populations 
able to induce MSC apoptosis. A-B: Apoptosis in MSCs cultivated with 
MLR-aPBMC used as unfractionated or positively selected for CD11b+, CD4+, 
CD8+ or CD56+ cells (A) or depleted of CD56+, CD8+ or both (B). In all 
experimental conditions, PBMC:MSC ratio was 20/1. Results represent the 
mean±SD of 3 or independent experiments. Statistics: one-way ANOVA, with 




To characterize the mechanisms mediating MSC apoptosis induced by 
activated cytotoxic cells, we studied potential factors involved in caspase 3 
activation and mediated by cytotoxic cells through the immunological 
synapse. We specifically assessed the role of GrB and perforin385,386, HLA-I, 
HLA-II complexes387, the adhesion molecule CD44388, the CXCL12/CXCR4 
axis389, the very late antigen-4 (VLA-4) (α4β1)/VCAM complex390, ICAM 
complex387, Integrins such as αVβ3 and CD18391, and the microtubule 
organizing center392. Furthermore, we assessed the role of CD95 (FAS), 
TNFα and TRAIL, since their importance in mediating extrinsic receptor-
mediated apoptosis393. 
 
The inhibition of either GrB or perforin completely abolished the ability of 
activated PBMCs to induce MSCs apoptosis (Figure 3.15A) and activate 
caspase 3 (Figure 3.15B, Video 3.5 and 3.6). In the presence of GrB and 
perforin inhibitors, annexin V+/7-AAD- MSCs were 7.8% (SD: 1.81, 95% CI: 
3.30-12.33) and 8.9% (SD: 4.83, 95% CI: -3.03-20.96), respectively, thus 
significantly reduced in comparison with the percentage of apoptotic MSCs 
obtained in the absence of any inhibition (43.43%, SD: 14.7, 95% CI: 6.90-
79.96) (Figure 3.15A). Similarly, caspase 3 activity, calculated as described 
by He and colleagues380, was 3519 (SD: 323.7, 95% CI: 2715-4323) in the 
positive control culture (MSC/MLR-activated PBMCs without inhibitors), while 
it was 102.6 (SD: 3.54, 95% CI: 70.73-134.4) and 845.2 (SD: 731.3, 95% CI: 
-5726-7416) in the presence of GrB or perforin inhibitors, respectively (Figure 
3.15B). We also observed reduced PBMC-mediated cytotoxicity when CD95 
ligand (CD95L, also known as FasL or APO-1L) was neutralized (Figure 
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3.15C). In contrast, MSC apoptosis was not reduced when TNFα or TRAIL 
were inhibited, even in the presence of very high concentrations of their 
respective inhibitors (Figure 3.15D). 
 
We then interrogated the nature of the MSC-cytotoxic cell interaction. We 
observed that apoptosis was not affected by the presence of anti-HLA class 
I- or anti-HLA class II neutralizing antibodies. Consistently, the cytotoxic 
activity of activated PBMCs against autologous or allogeneic MSCs did not 
differ (Figure 3.15E). However, although PBMCs required physical contact 
with MSCs to induce apoptosis (Figure 3.15F), blocking immunological 
synapse formation by inhibiting the polarization of microtubule organizing 
center392 had no effect (Figure 3.15G). Similar results were obtained when 
the adhesion molecule CD44, the CXCL12/CXCR4 axis, the VLA-4 
(α4β1)/VCAM complex, ICAM complex, or integrins such as αVβ3 and CD18, 
were neutralized by specific antibodies or antagonists. These results 
demonstrate that MSC killing by activated cytotoxic cells is a bystander effect 
that does not involve the immunological synapse.
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Figure 3.15. MSC apoptosis is mediated by Gr B/perforin and FAS/FAS-






Figure 3.15. MSC apoptosis is mediated by Gr B/perforin and FAS/FAS-
L and is the result of a bystander effect. A: Apoptosis in MSCs cultivated 
with MLR-aPBMC in the presence or absence of the GrB inhibitor Z-AAD-
CMK (300 µM) or the perforin inhibitor ethylene glycol-bis(2aminoethylether)-
N,N,N’,N’-tetraacetic acid (EGTA) (4 mM). B: MSCs were transfected with the 
pECFP-DEVDR-Venus vector (FRET-MSC) and FRET between pECFP and 
Venus-YFP FRET was studied by flow-cytometry and Caspase activity (CAf) 
calculated as described in Materials and Methods380. FRET-MSCs were 
cultured alone, with PHA-aPBMCs, or PHA-aPBMCs (at a PBMC:MSC ratio 
40:1) in the presence of GrB inhibitor or the perforin inhibitor as in A. C: 
Apoptosis in MSCs cultivated with PHA-aPBMCs in the presence or absence 
of neutralizing concentrations (10 µg/ml and 100 µg/ml) of FAS-L mAb anti-
CD178. D: MLR-aPBMCs were cultivated with MSCs. Where indicated, the 
TNF-α inhibitor Etanercept or the mAb anti-TRAIL were used at 10 µg/ml or 
100 µg/ml. E: Apoptosis in MSCs after culture with autologous (black bars) or 
allogeneic (grey bars) PHA-aPBMCs in the presence or absence of 
neutralizing doses of anti-HLA-A-B-C or anti-HLA-DR antibodies. The white 
bar shows spontaneous apoptosis in MSCs plated alone. F: Apoptosis in 
MSCs cultivated with MLR-aPBMCs in direct contact or in a transwell. G: 
Apoptosis in MSCs cultivated with PHA-aPBMCs in the presence or absence 
of escalating doses (10 to 75 µM) of PKCζ-PS. H: Apoptosis in MSCs 
cultivated with PHA-aPBMCs in the presence or absence of escalating doses 
of AMD3100 (antagonist of CXCR4, for blockage of the CXCL12/CXCR4 
axis), and of neutralizing antibodies against Integrin CD18 and αVβ3, CD29 
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(which forms with CD49d VLA-4), the adhesion molecule CD44, ICAM1, 
ICAM2 and VCAM1. In A, C-H the PBMC:MSC ratio was 20:1. In all settings, 
MSC apoptosis was evaluated by flow-cytometry after 4 hours of co-
incubation. Results represent the mean±SD of 3 (A-E, and G) or 6 (F) 
independent experiments. Statistics: one-way ANOVA, with Tukey’s Multiple 
Comparison Test. **: p<.01. ***: p<.001. ns: not significant.
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3.2.5 MSC apoptosis does not interfere with the recognition 
of the specific target of cytotoxic cells. 
 
Having determined that the MSC apoptosis induced by cytotoxic cells is MHC-
independent and not antigen-specific, we asked whether MSCs could exert 
their immunosuppressive effects by competing with and antagonizing 
antigen-specific recognition. NY-ESO1-specific CD8+ T cell clone (4D8) or 
IL2-activated polyclonal CD56+ purified NK cells were used as effector cells 
against NY-ESO-1 peptide (SLLMWITQC)-pulsed T2 or K562 cells, 
respectively. Two different sets of experiments were performed. In the first 
set, 4D8 or NK cells were tested against fixed numbers of putative 
(susceptible) target cells in the presence of escalating numbers of MSCs used 
as a cold target. The alternative condition consisted of escalating the numbers 
of the putative target cells – now used as cold targets – in the presence of a 
fixed number of MSCs then considered as the susceptible target. MSCs did 
not compete with antigen-specific T cell cytotoxicity since the killing of 
peptide-pulsed T2 cells was not affected by the presence of MSCs (Figure 
3.16A). The same results were obtained using NK cells (Figure 3.16B). In 
contrast, the presence of the putative target cells markedly reduced MSC 
killing in a dose dependent manner in both systems (Figure 3.16C and D). 
Our data show that MSC killing does not interfere with the primary recognition 
of the cognate antigen.
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Figure 3.16. MSCs do not compete with cytotoxic cell recognition of the 
cognate target. A: Apoptosis in T2-cell after culture with 4D8 cells at a 20:1 
4D8:T2 ratio. Where indicated increasing concentrations of MSC (used as 
cold target) were added. Apoptotic T2 cells were identified as annexin-V+/7-
AAD+ cells. B: Apoptosis in K562 cultured with NK cells (20:1 NK:K562 ratio). 
Where indicated increasing concentrations of MSC (used a cold target) were 
added. C: Apoptosis in MSC cultured with 4D8 cells (20:1 4D8:MSC ratio). 
Where indicated increasing concentrations of T2 cells (used as cold target) 
were added. D: Apoptosis in MSC cultured with NK cells at a 20:1 NK:MSC 
ratio. Where indicated, increasing dilutions of K562 (used as cold target) were 
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added. In all experiments, apoptosis of MSCs, T2 or K562 cells was assessed 
after 4 hours of co-culture by flow cytometry. Results represent the mean±SD 
of 3 independent experiments. Statistics in A, B, C and D: one-way ANOVA 
and Tukey’s Multiple comparison test. *: p<.05.
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3.2.6 MSCs are not immunosuppressive in the absence of 
cytotoxic cells in a Th2-type inflammation model. 
 
Our data imply that, since MSC killing does not interfere with the primary 
recognition of the cognate antigen, induction of apoptosis must be 
prominently involved in the immunosuppressive activity. Accordingly, in the 
GvHD model described above, MSC apoptosis produced by recipient 
cytotoxic cells is required for immunosuppression. Therefore, we asked 
whether this causative relationship remains valid in a different disease model 
associated with non-cytotoxic Th2-type inflammation. 
 
We selected the model of OVA-induced allergic airway inflammation376 
summarized in Figure 20A. Although cytotoxic immune cells have been 
implicated as contributing to the induction of this condition394,395, CD8+ and 
NK1.1+ cells infiltrating BAL and lung tissues were less than 2% one hour 
after the last OVA challenge, when MSCs were infused (Figure 3.17B-E).
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Figure 3.17. Mouse model of Th2-type inflammation model: absence of 




Figure 3.17. Mouse model of Th2-type inflammation model: absence of 
cytotoxic cells in lungs and BAL. A: Balb/C mice were immunized i.p. with 
OVA at day 0 and 7 and subsequently challenged with OVA through aerosol 
at days 14, 15 and 16 (OVA group). Experimental group was treated with 
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MSCs one hour after the last challenge (OVA+MSC). When luc-MSCs were 
used, mice were imaged one hour after infusion for the analysis of caspase 3 
activation after i.p. injection of DEVD-aminoluciferin. After 18 hours from 
treatment, eosinophil infiltration in BAL was evaluated. B-E: Percentage (B, 
D) and absolute numbers (C, E) of different cellular types in the BAL (B, C) 
and lungs (D, E) of naïve (with bars) (N=3) and OVA-sensitized (black bars) 
(N=3) mice. Results represent the mean±SD of 3 independent experiments. 




To confirm the absence of MSC killing, mice received luc-MSCs to assess 
caspase activation after infusion and imaged one hour later. No caspase 
activation was detected in any of the mice (Figure 3.18A and B). To confirm 
that luc-MSCs can be tracked in the lungs of all animals, we subsequently 
infused mice with the control D-luciferin. We could find that high signal could 
be detected from all animals (Figure 3.18C), with not significant difference 
among groups. Mean TLS were 120.7 (SD: 63.62, 95% CI: 53.95-187.5), 
and 125.4 (SD: 36.11, 95% CI: 35.7-215.1) in OVA+MSCs and naïve mice, 
respectively (Figure 3.18D). 
 
The therapeutic activity assessed by quantitating the eosinophil infiltration in 
the BAL showed no difference between MSC-treated and untreated mice 
(Figure 3.18E). Together, these results indicate that also in this model MSC 




Figure 3.18. MSCs do not have immunosuppressive activity in vivo in 




Figure 3.18. MSCs do not have immunosuppressive activity in vivo in 
the absence of induced apoptosis in a Th2-type inflammation model. A: 
luc-MSCs were injected into naïve (N=3) and OVA+MSCs (N=6) mice one 
162 
 
hour after the last challenge. One hour later, mice received DEVD-
aminoluciferin and were imaged in 3 independent experiments. White lines 
separate multiple photographs assembled in the final image. B: TLS was 
measured from Fig. 6A (mean±SD). C: In order to confirm the presence of 
luc-MSCs in the lungs of all groups of mice infused with MSCs, the same mice 
imaged in A were injected with D-Luciferin. White lines separate multiple 
photographs assembled in the final image. D: TLS was measured from the 
images of mice in Fig. S6F and shown as mean±SD. Statistics: unpaired t-
test. ns: not significant. E: Eighteen hours after MSC infusion, eosinophil 
infiltration was assessed in the BAL of naïve (N=3), naïve infused with MSCs 
(N=3), OVA (N=6) and OVA+MSCs (N=6) mice in two independent 





This study sheds light on the controversial topic of MSC therapeutics by 
identifying a crucial mechanism that potentially explains several unresolved 
issues in the field. The first striking piece of information provides the 
resolution to the paradox that MSCs are therapeutically efficacious despite 
the lack of engraftment396–398. 
 
We have demonstrated that MSCs undergo extensive caspase activation and 
apoptosis after infusion in the presence of cytotoxic cells, and that this is a 
requirement for their immunosuppressive function. 
 
Our results are in line with previous studies, whereby activated but not resting 
NK cells were able to lyse MSCs in vitro46, or MSCs were cleared in vivo by 
deployment of different recipient-dependent reactions397–401. Along with these 
observations, our data challenge the notion of MSCs as immunopriviledged. 
This assumption was based on the acknowledged property of MSCs to 
express low or no levels of HLA-I, HLA-II or other co-stimulatory molecules 
(such as CD40, CD80 or CD86)1, and was supported by the MSC ability to 
immunosuppress rather than fail to present antigens in vitro44,402,403, and to 
be therapeutic effective across the MHC barrier both in animal models404 and 
in humans in vivo26,329. Notably, the results of our study are the first showing 
the instrumental role of in vivo MSC apoptosis in delivering 
immunosuppression after infusion, thus reconciling the role of the 
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demonstrated MSC rejection405 in the context of their immunosuppressive 
functions across MHC barrier26,329,404. 
 
Furthermore, although several studies375,406–408 have reported the ability of 
apoptotic cells to modulate immune responses, here we provide evidence that 
in vivo naturally occurring cell death drives immunosuppression. 
 
MSC apoptosis requires and is induced by cytotoxic granules contained in 
recipient cytotoxic cells that also mediate GvHD in recipient mice. Importantly, 
the cytotoxic activity against MSCs can also be detected in the PBMCs of 
GvHD patients and this is predictive of clinical responses. Recently, analysis 
of plasma markers in patients serially monitored before and after MSC 
treatment has highlighted the role of a panel of biomarkers (including 
regenerating islet-derived 3-α, TNF receptor 1, IL-2 receptor alpha, soluble 
cytokeratin 18 and elafin) as predictors of GVHD-related mortality297. 
Accordingly, most of them were selectively reduced in patients responding to 
MSCs10,11. However, the role of these markers seems to be confined to the 
early assessment of response after treatment, rather than their use as 
response predictors. In contrast, our data show that patients displaying high 
cytotoxicity respond to MSCs, whilst those with low or absent cytotoxic activity 
do not improve following MSC infusion. Therefore, the ability of the recipient 
to generate apoptotic MSCs appears to be a requirement for the therapeutic 
efficacy and could be used as a potential biomarker to stratify patients for 
MSC infusions before the treatment. Importantly, among the several 
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parameters evaluated, only the results of the cytotoxic assay were 
significantly predictive of the response to MSCs. This was not surprising, 
considering the high specificity and sensibility of the test. However, the limited 
number of patients analyzed warrants further validation in a prospective 
clinical study. Moreover, characterizing the phenotype of the cytotoxic cells 
mediating MSC apoptosis in patients will enable the development of a more 
approachable assay for use in a routine pathology laboratory. 
 
One of the impacts of our study is that, although MSCs remain the necessary 
starting point for therapeutic immunosuppression, patient-derived cells play a 
crucial role in delivering such an immunosuppression. This new perspective, 
in line with clinical data whereby MSCs from the same donor can give different 
responses in different patients327–331,338,339, may significantly affect the 
Research and Development sector of MSC manufacturing. In the last 
decades, many efforts have been spent for the identification of the most 
clinically effective MSC preparations. Several strategies have been proposed, 
including the selection of MSCs based on biological parameters such as the 
magnitude of IDO synthesis83 or the intracellular levels of the transcription 
factor TWIST1410. Conversely, other groups suggested to overcome the 
intrinsic variability among MSC batches by using MSCs sourced from different 
donors and pooled together during the expansion phase411. Our results seem 
to suggest that MSCs exhibit similar capacity to undergo apoptosis, despite 
different batches were used (Figure 3.10). However, the cells used in this 
study were all sourced from BM and expanded using the same protocol. 
Further studies are needed to verify whether MSCs from different sources, 
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administered after thawing or from fresh cultures, expanded in selected 
conditions, or differentially sorted based on specific features have different 
“capacity” to be killed. In this perspective, the cytotoxic assay may be devised 
as a tool for standardization of MSC manufacturing by select specific 
thresholds of killing used as product specification. Such an assay would also 
address the unmet need for a potency assay as a guideline for regulatory 
Authority requirements412 to implement quality control of manufactured 
MSCs. 
 
This perspective would be a complete upturn of the concept of potency assay 
in the MSC therapeutics. Most potency assays are designed with the aim to 
identify or select the “most immunosuppressive” MSC batches413,414, but they 
are exclusively based on MSC in vitro properties. By measuring their 
susceptibility to undergo apoptosis when exposed to cytotoxic cells, our assay 
would identify the most ‘fit MSCs’, at least if administered to patients able to 
induce their apoptosis. 
 
MSC recognition by cytotoxic cells is not antigen specific as neither requires 
HLA engagement, nor results from an alloreactive rejection, thus supporting 
the current practice of using third-party MSCs. MSCs must be in physical 
contact with the activated cytotoxic cells to undergo apoptosis, although 
immunological synapse is not required. This supports a bystander role for the 
cytotoxic granules released by the activated cytotoxic cell. Accordingly, it has 
been described that lytic granule secretion precedes the formation of 
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cytotoxic T lymphocyte/target cell synapse392. Furthermore, such a non-
specific mechanism can mediate tissue damage in the context of human 
immunodeficiency virus replication415 or atherosclerosis416 whereby activated 
CD4+ or NK T cells have been implicated in the progression of human 
immunodeficiency virus infection or the atherosclerotic disease, respectively. 
In these studies, bystander cells are not of mesenchymal origin, thus raising 
the interesting question, that we have not addressed here, of whether non-




4 Apoptotic MSCs are immunosuppressive and 





In the previous Chapter we have demonstrated that when MSCs are infused 
into a recipient harbouring activated cytotoxic cells they are induced to 
undergo apoptosis and that this apoptosis is necessary to deliver 
immunosuppression. Furthermore, the cytotoxic activity of GvHD patients 
could be used as a biomarker to predict clinical outcome. 
 
Although these results represent important steps forward in the improvement 
of MSC therapeutics, they do not explain how apoptotic MSCs exert their 
tolerogenic properties in vivo. Furthermore, the results imply that a significant 
proportion of GvHD patients cannot benefit from this treatment, because they 
do not induce MSC apoptosis. 
 
It is well-known that clearance of apoptotic cells in the steady-state is mostly 
an immunological silent event417. A crucial role in controlling the potential 
inflammation is played by phagocytic cells which clear apoptotic cells by 
engulfing them. Following this phenomenon, called efferocytosis, phagocytes 
169 
 
acquire a tolerogenic phenotype that exert potent immunosuppression374,418. 
By mimicking this process, several groups have used apoptotic cell-based 
approaches to treat pre-clinical models of immune mediated diseases375, 
prolong survival of transplanted organs419, or prevent GvHD420. Based on 
these assumptions, we tested the hypothesis that MSCs made apoptotic in 
vitro could exert in vivo therapeutic activity also in the absence of cytotoxic 





4.2.1 Apoptotic MSCs are immunosuppressive in a Th2-type 
inflammation model. 
 
First, we decided to test whether in vitro generated apoptotic MSC 
(ApoMSCs) could bypass the need of cytotoxic cells and ameliorate 
eosinophil infiltration. Based on the observation that MSC apoptosis was 
induced in vitro by activated PBMCs through the release of GrB/perforin, 
along with involvement of the FAS/FAS-L pathway signaling (Figures 3.15A-
C), we optimized the generation of apoptotic MSCs in vitro (ApoMSCs) by 
using recombinant GrB and a monoclonal antibody activating human FAS 
(Figure 4.1B and C). 
 
When ApoMSCs were administered to recipient mice we observed that the 
eosinophil infiltrate in BAL was much reduced, even at extremely low doses. 
Indeed, eosinophil infiltration in BAL was 21.45x104/ml (DS: 7.57, 95% CI: 
13.49-29.40) in OVA only mice (n=6), 8.28x104/ml (DS: 7.29, 95% CI: 1.53-
15.03) in OVA mice treated with 1x106 ApoMSCs (n=7), 9.01x104/ml (DS: 
3.67, 95% CI: 6.18-11.84) in mice treated with 2x105 ApoMSCs (n=9) and 
5.2x104/ml (DS: 4.24, 95% CI: 0.74-9.65) in mice treated with 4x104 
ApoMSCs (n=6). No eosinophil infiltration could be found in naïve Balb/C 
mice receiving 1x106 or 2x105 ApoMSCs (Figure 4.1D). The anti-
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inflammatory effect was caspase dependent because it was reverted by 
generating ApoMSCs in the presence of Z-VAD-FMK (Figure 4.1E).
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Figure 4.1. Apoptotic MSCs exert in vivo immunosuppression despite 




Figure 4.1. Apoptotic MSCs exert in vivo immunosuppression despite 
the absence of cytotoxic cells. A-B: MSCs were treated with different 
concentrations of recombinant human GrB and monoclonal antibody against 
human FAS (activating) in order to optimize the generation of in vitro apoptotic 
MSCs (ApoMSCs). Level of apoptosis was assessed by flow-cytometry after 
12 (A) or 24 hours (B) of treatment. The most effective treatment selected 
was GrB/FAS (5/10 µg/ml) for 24 hours, which is able to generate a mean of 
88.5% (SD: 1.56, 95% CI: 74.52-102.5) apoMSCs. C: Th2-induced airway 
inflammation was obtained in Balb/C mice as in Figure 3.17A. Where 
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indicated different doses of ApoMSC (1x106, 2x105 and 4x104) were injected 
1 hour after the last challenge. Eosinophil infiltration in BAL was then 
evaluated after additional 18 hours. The results of three independent 
experiments are shown. Statistics: 1-way ANOVA and Hommel post-hoc test. 
D: Balb/C mice were treated as in C and injected 1 hour after the last 
challenge with ApoMSCs or ApoMSCs obtained adding the pan-caspase 
inhibitor Z-VAD-FMK during the 24 hours of incubation (Z-ApoMSCs). 
Eosinophil infiltration in BAL was evaluated after additional 18 hours and was 
61.82x104/ml (DS: 41.62, 95% CI: 23.33-100.30) in OVA only mice (n=7), 
37.19x104/ml (DS: 38.41, 95% CI: 7.65-66.71) in OVA mice treated with 2x105 
ApoMSCs (n=9) and 62.59x104/ml (DS: 48.25, 95% CI: 17.96-107.2) in mice 
treated with 2x105 Z-ApoMSCs (n=7). C-D: Results of three independent 
experiments are shown. Statistics: 1-way ANOVA and Hommel post-hoc test. 
**: p<.01, ***: p<.001. ns: not significant.
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4.2.2 Apoptotic MSCs infused in GvHD are 
immunosuppressive and induce IDO production in 
recipient phagocytes. 
 
We subsequently investigated whether ApoMSCs could be 
immunosuppressive also in the GvHD model. ApoMSCs were administered 
either i.v. or i.p. at day +1, +3, and +6 after the transplant, and the infiltration 
of CD8+Vβ8.3+ Mh T cells was assessed and compared to untreated GvHD 
mice at day +7. ApoMSCs produced a substantial reduction in GvHD effector 
cell infiltration in both spleen and lungs. Mean percentage infiltration of Mh T 
cells was 7.58% (SD: 2.05, 95% CI: 5.86-9.29) and 11.72 (SD: 3.04, 95% CI: 
9.55-13.89) in the spleen of ApoMSC treated and untreated GvHD mice, 
respectively (Figure 4.2A). In lungs the percentage of CD8+Vβ8.3+ GvHD 
effector cells was 14.18% (SD: 7.83, 95% CI: 7.64-20.73) and 18.97% (SD: 
6.95, 95% CI: 14.00-23.94) in treated and untreated mice, respectively 
(Figure 4.2B). Importantly, this immunosuppressive effect could not be 








Figure 4.2. ApoMSCs exert immunosuppressive activity in GvHD. A-D: 
The percentage of GvHD effector cells was assessed in the lymphocyte gate 
in spleen (A, C) and lungs (B, D) of GvHD mice (black circles) and GvHD 
mice treated with ApoMSCs (black squares). ApoMSCs were infused i.p. 
(GvHD mice N=10, GvHD+ApoMSC mice N=8) (A, B), or i.v. (GvHD mice 
N=9, GvHD+ApoMSC mice N=7) (C, D). Results represent the mean±SD of 




It has been reported that the injection of irradiated thymocytes into animals results in 
their phagocytosis by recipient macrophages and induction of IDO374. We therefore 
tested whether ApoMSCs followed the same destiny by eliciting in vivo efferocytosis 
by recipient phagocytes and inducing IDO production. For this purpose, labelled 
ApoMSCs were traced in recipient phagocytes after injection. Following i.p. 
administration, ApoMSCs were largely identified inside CD11b+ (Figure 4.3A) and 
CD11c+ (Figure 4.3B) phagocytes in the peritoneal draining lymph nodes421 but absent 
when searched for in the lungs and spleen. When the i.v. route was used, amongst 
the several phagocytic populations investigated422, CD11bhighCD11cint (residual vessel 
patrolling monocytes/mature CD11b+ cDCs), CD11bhighCD11c- (circulating 
monocytes) and CD11b-CD11c+ (DCs) were detected as engulfing ApoMSCs in lungs 
(Figure 4.3C-E). The analysis of IDO expression in the phagocytes engulfing 
ApoMSCs both in the i.v. and i.p. groups revealed that only the phagocytes in the i.p. 
group were able to increase IDO expression in comparison with their counterparts in 
untreated GvHD mice (Figure 4.3F and G). These findings strongly suggest that the 










Figure 4.3. ApoMSCs elicit IDO in engulfing recipient phagocytes. A-G: 
MSCs were labelled using CellTrace™ Violet and subjected to apoptosis 
induction using GrB/FAS-L (5 µg/ml and 10 µg/ml, respectively). Labelled 
ApoMSCs were injected i.p. (A, B and F) or i.v. (C, D, E and G) into GvHD 
mice 3 days after the transplant. After 2 hours, animals were sacrificed and 
mesenteric lymph nodes (LN) (A, B and F) or lungs (C, D, E and G) were 
harvested. Cells engulfing ApoMSCs were identified as Violet+ cells within the 
CD11b+ (A), CD11c+ (B), CD11bhighCD11cint (C), CD11c+CD11b- (D), and 
CD11bhighCD11c- (E) subpopulations. The corresponding subpopulations 
were gated in GvHD mice which had not received violet labelled ApoMSCs 
and used as controls. F and G: IDO expression was assessed in CD11c+ and 
CD11b+ (F) or CD11bhighCD11cint, CD11c+CD11b- and CD11bhighCD11c- (G) 
cells positive for CellTraceTM Violet (engulfing ApoMSCs) and compared with 
the corresponding populations in GvHD mice that had not received 
ApoMSCs. Data are representative of similar results obtained from three mice 
in 2 independent experiments.
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4.2.3 Recipient IDO-producing phagocytes are indispensable 
for MSC immunosuppression in GvHD. 
 
To directly test the importance of recipient-derived phagocytes and IDO 
activity in MSC immunosuppressive activity, we depleted phagocytes and 
inhibited IDO activity in GvHD mice before MSC treatment and evaluated the 
effect of live MSCs on the expansion of GvHD effectors. To deplete 
phagocytes, liposome clodronate was given to mice 72 hours before MSC 
injection374. The treatment substantially impaired the ability of MSCs to 
suppress Mh T cell infiltration (Figure 4.4A and B).  
 
Finally, animals were given the IDO inhibitor 1-methyl-D-tryptophan (1-
DMT)375 before MSC injection. Also in this case, the beneficial effect of MSCs 
on Mh T cell infiltration was much reduced in mice receiving 1-DMT compared 
to controls (Figure 4.4C and D). However, these results do not definitely 
exclude that IDO could be produced, at least in part, by the apoptotic MSCs. 
If this was the case, also ApoMSCs by themselves could have mediated the 
generation of tolerogenic phagocytic cells. To address this question, we 
evaluated the IDO gene expression in ApoMSCs by real time PCR after 12 
and 24 hours of incubation with GrB and FAS. Our findings demonstrated that 





We therefore conclude that the immunosuppressive effect of MSCs requires 




Figure 4.4. Recipient phagocytes and IDO production are required for 




Figure 4.4. Recipient phagocytes and IDO production are required for 
MSC immunosuppressive activity in GvHD. A, B: GvHD mice were treated 
with liposomal clodronate 10 minutes after the transplant. Where indicated, 
MSCs were infused 3 days later. The percentage of GvHD effector cells 
(CD8+Vβ8.3+) were calculated in the lymphocyte gate in spleen (A) or lungs 
(B) after 4 additional days. Mean±SD was obtained grouping three 
independent experiments with N: 12 (GvHD) and 10 (GvHD+MSCs) mice per 
group. C, D: GvHD effector cell infiltration was studied in spleen (C) and lungs 
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(D) of GvHD mice treated with the IDO-inhibitor 1-DMT. In the treated mice, 
MSCs were infused 3 days after the transplant (N=11). Controls consisted of 
GvHD mice which did not receive MSCs (N=9). Percentage of CD8+Vβ8.3+ 
cells refers to the lymphocyte population. Results refer to the mean±SD of 3 
independent experiments. Statistics: unpaired t-test. *: p<.05; **: p<.01. ns: 
not significant. D: MSCs were incubated for 12 or 24 hours with GrB (5 µg/ml) 
and activating FAS (10 µg/ml) to generate ApoMSCs. IDO expression was 
assessed by real time PCR and calculated as relative expression in 
comparison to that of untreated (live) MSCs. Representative results of two 
independent experiments are shown.
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4.2.4 Recipient-derived IDO is indispensable for ApoMSC 
immunosuppression in a Th2-type inflammation model. 
 
To assess that also the immunosuppressive activity delivered by ApoMSCs 
was dependent on IDO produced by MSC-recipients, OVA-treated animals 
were given the IDO inhibitor 1-DMT375 before ApoMSC injection. As in the 
GvHD model, the beneficial effect of ApoMSCs on eosinophil infiltration was 
abolished in mice receiving 1-DMT. Hence, also in the case of MSCs made 
apoptotic in vitro, their anti-inflammatory effect requires IDO production by the 
host (Figure 4.5). We therefore conclude that the anti-inflammatory effect of 
ApoMSCs generated ex vivo requires the presence of IDO in the host 
receiving MSCs also in this model.
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Figure 4.5. IDO production by apoMSC recipient is required for 
immunosuppression in a Th2-type inflammation model. 
 
 
Figure 4.5. IDO production by apoMSC recipient is required for 
immunosuppression in a Th2-type inflammation model. Balb/C mice 
were treated as in Figure 20A and injected with ApoMSCs (2x105) 1 hour after 
the last challenge. Eosinophil infiltration in BAL was then evaluated after 
additional 18 hours. Where indicated mice were treated with 1-DMT in the 
drinking water (2 mg/ml) starting 6 days before MSC injection. Eosinophil 
infiltration was 99.42x104/ml (DS: 57.47, 95% CI: 39.11-159.70) in OVA only 
mice (n=6), 45.24x104/ml (DS: 32.98, 95% CI: 10.63-79.85) in OVA mice 
treated with ApoMSCs (n=6), 133.5x104/ml (DS: 76.95, 95% CI: 37.96-229.1) 
in OVA mice treated 1-DMT (n=5), 110.3x104/ml (DS: 54.28, 95% CI: 60.06-
160.5) in OVA mice treated with ApoMSCs and 1-DMT (n=7) and 2.31x104/ml 
(DS: 0.39, 95% CI: 1.32-3.30) in naïve mice treated with 1-DMT (n=3). 
Results of two independent experiments are shown. Statistics: 1-way ANOVA 





In this Chapter we have shown that MSCs made apoptotic in vitro exert potent 
immunosuppression in both a preclinical model of aGvHD and in a Th2-type 
inflammation model of lungs. These regulatory functions are mediated 
through the production of IDO by the phagocytic cells engulfing ApoMSCs. 
 
Our data further support an approach to MSC therapeutics that highlights the 
key role of MSC recipient to orchestrate and determine MSC effector 
functions as discussed in the previous Chapter. Not only are cytotoxic cells in 
the recipient required to initiate apoptosis in infused MSCs (Chapter 3), but 
also phagocytes which, by engulfing apoptotic MSC and producing IDO, 
ultimately deliver MSC immunosuppressive activity. 
 
The link between phagocytosis of apoptotic MSCs, induction of tolerogenic 
phagocytes and IDO production has important implications in the design of 
future clinical trials employing MSCs. The monitoring of tolerogenic 
phagocytic populations of cells may be devised as a biomarker of response 
after treatment, as also suggested by the observation of a more marked 
increase of circulating tolerogenic DCs in aGvHD patients who responded to 
MSCs in comparison with non-responding patients297. Furthermore, the 
possibility to assess kynurenines in serum samples423, or to track IDO activity 
in vivo with analogues of Tryptophan which can be imaged with positron 
emission tomography424, might open the way to the development of new 
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surrogates of outcomes based on IDO activation. Although still at a very early 
stage, these new hints warrant further investigations. 
 
The use of cells made apoptotic before infusion is an intriguing approach 
which have been attracting much attention in solid and BM transplant 
management407. Also in GvHD, the use of patient white blood cells made 
apoptotic after exposure to photoactivatable 8-methoxypsoralen and 
ultraviolet A radiation (extracorporeal phonophoresis [ECP]) is a 
consolidated, although not standardised, therapy in steroid resistant 
patients425,426. 
 
The mechanisms unveiled in this chapter are in line with those reported to 
explain how apoptotic cells of different lineages, generated in vitro, induce 
immune modulation in GvHD406–408, and macrophage IDO production in other 
systemic autoimmune diseases375. 
 
The depletion of recipient macrophages or the inhibition of IDO activity also 
impairs the therapeutic activity of live MSCs, thereby linking in vivo MSC 
apoptosis with immunosuppression. It is unlikely that any particular 
phagocyte population (macrophages or dendritic cells) is selectively involved 




The crucial role advocated for phagocytic cells as ultimate effectors of the 
immunosuppressive tolerogenic effect mediated by MSCs is consistent with 
the described ability of MSCs to stimulate recipient immune tolerance 
networks, macrophages and DCs (Chapter 1). In this study we have not 
analysed the role of Treg cells. This would have required an analysis taking 
into account the kinetics of Treg cell generation as well as their localisation 
and trafficking. Furthermore, recipient myeloablation could be a confounding 
factor because it is associated with a homeostatic expansion that has been 
reported to selectively prime Treg cell expansion427,428. 
 
 However, it is conceivable that stimulation of IDO production in macrophages 
and DCs after engulfment of apoptotic MSCs (generated in vivo or in vitro) 
may be one of the mechanisms employed for the generation of Treg cells in 
vivo after MSC infusion, since IDO is implicated in the expansion of regulatory 
T cells (Chapter 1). 
 
Another important impact of this study is that the administration of ex-vivo 
generated ApoMSCs can circumvent the requirement for cytotoxic cells in a 
Th-2 type inflammatory model. The fact that ApoMSCs can be effective at 
suppressing the expansion/infiltration of the GvHD effector cells supports the 
idea that this therapeutic tool may be exploited to treat those aGvHD patients 
who do not respond to MSCs because deficient in those cytotoxic cells able 
to induce MSC apoptosis. Interestingly, ApoMSCs were mostly effective in 
the GvHD model only when administered i.p. Despite being phagocytosed, 
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ApoMSCs injected i.v. did not induce IDO production, thus suggesting that 
the site at which MSC apoptosis occurs may influence the 
immunosuppressive function, perhaps by engaging with a subpopulation of 
phagocytes. Therefore, a more thorough characterization of the 
administration modality is required before testing ApoMSCs in the clinical 
setting. 
 
Our data indicate that MSC apoptosis is sufficient to deliver a therapeutic 
activity in two different disease models, thus indicating that, at least in our 
experimental conditions, the cytokine-mediated ‘licensing’ (see Chapter 1) is 
not required for MSC immunosuppression. However, we cannot exclude that, 
before undergoing apoptosis, MSCs directly inhibit inflammatory reactions 
through the conventional pathways. Furthermore, caspase activation in 
MSCs may trigger cell-death independent pathways that stimulate the 
synthesis of immunomodulatory molecules independently of the generation 
of signals for phagocytosis429. Consistent with this, it has been shown that 
MSCs activate caspase-dependent IL-1 signaling that enhances secretion of 
immunomodulatory molecules136. 
 
Our data on the role of MSC apoptosis and the possibility to employ MSCs 
already made apoptotic in vitro before infusion open important questions 
which may be clinically relevant in specific settings and thus need to be 
addressed in future studies. One first question is whether the antigen 
repertoire of MSCs could have a role in mediate antigen specific tolerance. 
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This issue may be relevant when MSCs are used for the prevention or 
treatment of solid organ transplant rejection. Indeed, it has been reported in 
a mouse model of hearth transplantation that prolonged survival of the graft 
could be obtained only when MSCs and tolerized grafts shared part of their 
antigens, but not when they were completely disparate237. 
 
The final question is whether MSCs, once killed, may elicit an allo-specific 
immune response which may affect subsequent infusions of MSCs from the 
same donor. It has been demonstrated that MSCs rejected in allogeneic 
settings elicit an immune response with induction of memory cells both within 
the CD4+ and CD8+ compartments401. These memory cells were able to 
rapidly lysed MSCs upon re-infusion, and the killing was alloantigen-specific. 
If this will be confirmed also in the GvHD settings, it would support the 
usefulness of sequential infusion of MSCs, ideally from the same donor, 
whereby the previous infusion would boost the response to the next 
administration of cells. However, the usually severely immunocompromised 
status of the patient may be an obstacle to this strategy.
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5 Response to MSCs within the first week after 





In the previous Chapters we have demonstrated that MSCs undergo 
apoptosis after infusion. MSC apoptosis is instrumental for the therapeutic 
activity and requires the presence of cytotoxic cells in MSC-recipient. 
Deciphering this novel mechanism of action led us to the identification of a 
biomarker to predict clinical responses in GvHD patients treated with MSCs. 
Importantly, our functional assay was the only factor associated with a 
response to MSCs. 
 
Our responses were recorded as early as one week after MSC treatment. The 
choice of an early assessment was in line with our hypothesis that crucial 
events leading to the immunosuppression delivered by MSCs could take 
place early after infusion. Furthermore, it minimizes the risk of possible 
confounding effects of concomitant treatments on the response to MSCs. 
However, the clinical significance of an early assessment remains to be 
addressed, since the current practice to evaluate responses to MSC 




In this Chapter, we first analyzed the overall survival of the 32 patients 
enrolled in the study of the cytotoxic assay and described in Chapter 3, and 
we assessed whether evaluation of the response at 1 week had a significant 
impact on the survival of those patients. To confirm the clinical relevance of 
this early assessment, we performed a retrospective analysis of a cohort of 
60 steroid-resistant aGvHD patients treated with BM-MSCs in several centres 






5.2.1 Impact of assessing clinical response at 1 week after 
MSC treatment. 
 
To investigate the significance of assessing MSC treatment at 1 week, we 
evaluated the overall survival of the 32 patients who were enrolled in the study 
of the cytotoxic assay, described in Chapter 3. Patients characteristics are 
described in Table 3.1.  
 
The median OS of the whole cohort of patients was 72 days (95% CI: 78.06-
250.7 days) from GvHD diagnosis (Figure 5.1A), with a median follow-up of 
480 days for patients alive (range 91-592 days). Three patients (2 among the 
non-responders and 1 among responders) died because of relapse soon after 
MSC infusion and were excluded from the study. When patients were 
classified into responders and non-responders to MSCs, we could find a 
significant longer overall survival in those patients classified as responders. 
Median survival was 65 days or not reached in non-responders and 
responders, respectively (Figure 5.2B).  
 
These data demonstrated that assessment of the response at 1 week from 
MSC treatment did have clinical relevance.
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Figure 5.1. Overall survival of patients treated with MSCs. A: OS of the 
whole cohort of patients. B: OS of Responders and Non-responders. log-rank 
test, p<.02; hazard ratio: 0.27 (95% CI: of ratio 0.096 to 0.784). Median 
survival in Responders was not reached, while was 65 days in Non-
responders. Overall survival starts from GvHD diagnosis.
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5.2.2 Retrospective analysis of a cohort of 60 patients with 
steroid resistant GvHD treated with MSCs. 
 
Sixty steroid-resistant aGvHD patients treated with BM-MSCs at several 
Centres in the UK between May 2008 and December 2014 were 
retrospectively studied. Detailed demographics of patients are summarized in 
Table 5.1. 
 
Median age of patients was 40 years (4 months-68 years). Most of the 
patients were transplanted because of a haematological malignancy. 
Fourteen patients had AML, 10 patients had ALL, 10 had CML, 7 had MDS 
or MPNs, 11 patients were diagnosed with HL, NHL, or MM and 11 had other 
non-neoplastic diseases. 
 
All patients received GvHD prophylaxis with 3 or 4 doses of methotrexate 
combined with CSA, and T-cell depletion with alemtuzumab or ATG. aGvHD 
was biopsy proven in 46 (77%) patients, whilst in the remaining patients the 
diagnosis was based on clinical features after excluding alternative causes. 
 
Fifty-five (92%) patients had grade III or IV GvHD. Ten (17%), 16 (27%), and 
1 (2%) of patients had skin, gut, or liver involvement only, respectively. 16 
(27%) patients exhibited gut and skin, 11 (18%) skin, gut, and liver, 3 (5%) 
skin and liver, and 3 (5%) gut and liver. 
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Most of the patients of this cohort were heavily pre-treated. Indeed, 47 (78%) 
received MSCs after two or more therapies. When other drugs were used 
after steroids, the most used were MMF (n=30, 50%), monoclonal antibodies 
against TNFα (n=18, 30%), or CSA (n=17, 28%). Only in 13 (22%) patients, 
MSCs were given as second line treatment after methylprednisolone.
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Table 5.1. Patients’ characteristics. 
 
Total, number 60 
Age, years   
Median (Range) 40 (4mo-68) 
Sex, n   
Male 21 
Female 39 






NHL/HL/MM/Other Lymphomas 11 
Others 7 
Time from HSCT to MSC treatment, days   
Median (range) 62 (12-929) 
Time from aGvHD to MSC treatment, days 
 
Median (range) 60 (11-905) 
GvHD treatment before MSC infusion, n   
MEP Alone 13 
MEP in combination with other drugs 45 
Other drug combinations not including MEP 2 
CSA 17 
MMF 30 
Anti-TNFα (Infliximab, Etanercept) 18 
Tacrolimus 8 
MTX 3 
Anti-CD25 (Basiliximab, Daclizumab) 1 
ECP 3 
Anti-CD20 (Rituximab) 1 
Anti-CD52 (Alemtuzumab) 3 
ATG 1 
GvHD grade, number  
I-II 5 
III-IV 55 






aGvHD: acute Graft versus Host disease, AML: Acute Myeloid Leukemia, 
ALL: Acute Lymphoblastic Leukemia, ATG: anti-thymocyte globulin, CML: 
Chronic Myeloid Leukemia, CLL: Chronic Lymphocytic Leukemia, CSA: 
Cyclosporin, ECP: Extracorporeal photopheresis, HSCT: Hematopoietic 
Stem Cell Transplant, MDS/MPN: Myelodisplastic 
Syndrome/Myeloproliferative Neoplasms, MEP: Methylprednisolone, MMF: 
Mycophenolate, MSC: Mesenchymal Stromal Cells, MTX: Methotrexate, 
NHL/HL/MM: Non-Hodgkin Lymphoma/Hodgkin Lymphoma/Multiple 
Myeloma, TNFα: Tumor Necrosis Factor α.
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5.2.3 MSC treatment. 
 
Thirty-four patients (57%) received 1 dose of MSCs, while 19 (32%), 6 (10%) 
and 1 (2%) were treated with 2, 3, or 4 doses, respectively. Median time to 
first MSC administration was 62 days (12-929 days) from HSCT or 60 days 
(11-905 days) from GvHD diagnosis. The median dose of MSCs was 
2.6x106/Kg body weight per infusion (range: 0.6-15.6x106/Kg body weight). 
No significant adverse reactions were observed after infusion.
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5.2.4 Response to MSC treatment. 
 
Response to MSCs was assessed 1 week after treatment. Overall, 32 
patients (53%) responded, with 1 (1.6%) and 31 (51.6%) patients achieving 
CR or PR, respectively. Amongst patients who received multiples doses, in 
most cases subsequent doses did not change the type of response obtained 
after the first dose, except for two patients. One patient responded to the first 
dose with a PR, received a second one but relapsed a week after. The second 
patient achieved PR after the first dose and CR after the second. 
 
We then investigated whether we could identify factors associated with 
clinical responses. We found that patient gender, pre-MSC therapy, interval 
from HSCT or aGvHD diagnosis to MSC treatment, and grade of aGvHD did 
not affect clinical responses (Table 5.2). Conversely, organ involvement, age 
at HSCT and the dose of MSCs were significantly associated with the 
response rate to MSCs (Table 5.2). The proportion of responders was 28 
(67%) amongst patients with involvement of gut, skin, or both, but only 4 
(22%) amongst those with involvement of the liver (alone, or in combination 
with skin and/or gut). Patients younger than 20 years fared better, with 15 
(88%) of them responding to MSCs. Conversely, only 7 (30%) and 6 (43%) 
of those aged 20-50 years or older than 50 responded, respectively. Lastly, 
higher response rates (n=13, 77%) were observed in patients receiving MSC 
doses >3.0x106/Kg compared with patients receiving 1.5-3.0x106/Kg (n=18, 
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56%) or <1.5x106/Kg (n=1, 9%) (Table 5.2). All these 3 factors remained 
significant in multivariate logistic regression analysis (Table 5.3).
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Table 5.2. Analysis of factors affecting survival and response to 
treatment. 
 





Overall, number 60 3.4 (0-7.8) - 32 (53%) - 
Patient Gender, number 
   Male 














Patient age, years 
   <20 
   20-50 



















aGvHD treatment, number 
   MEP alone 
   MEP +1 other 




















Time from HSCT to MSCs, 
days 
   <60 
















Time from GvHD to MSCs, 
days 
   <60 














aGvHD grade, number 
   2 
   3 





















   Skin or Gut or Skin + Gut  















MSC dose, x106/Kg body-
weight 
   <1.5 
   1.5-3.0 



















Response to MSCs 
   Yes 












aGvHD: acute Graft versus Host disease, HSCT: Hematopoietic Stem Cell 
Transplant, MEP: Methylprednisolone, MSCs: Mesenchymal Stromal Cells.
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Table 5.3. Multivariate logistic regression analysis for disease 
response. 
 
 N Odds ratio (95%CI) P 
Patient age, years 
   <20 
   20-50 













aGvHD organ, number 
   Skin or Gut or Skin + Gut  










MSC dose, x106/Kg body-weight 
   <1.5 
   1.5-3.0 


















5.2.5 Analysis of Survival 
 
The estimated median OS of all patients was 104 days (95% CI: 0-215 days) 
(Figure 5.2A), with a median follow-up of 741 days for patients alive (range 
461–2521 days). Response to MSCs had a major impact on OS, with a longer 
estimated OS in responding patients compared with non-responders (Figure 
5.2B). 
 
We evaluated the association between OS and gender, age, pre-MSC 
therapy, interval from HSCT, or aGvHD diagnosis to MSC treatment, grade 
of aGvHD, organ involved, and the response to MSCs. By using both 
univariate and multivariate analysis, we found that the presence of any kind 
of response (CR or PR) assessed after 1 week from the first MSC infusion 








Figure 5.2. Probability of survival in patients treated with MSCs. A: 
Probability of Survival of the whole cohort of patients. B: Probability of 
Survival of Responders and Non-responders. log-rank test, p<.0001; hazard 
ratio: 0.2. Median survival in Responders was not reached, while was 20 days 






The data described in this chapter strongly support the clinical relevance of 
assessing response 1 week after MSC administration. Responders defined 
at this time-point exhibited a much longer overall survival in comparison with 
non-responders. Our observation is reinforced by the fact that this finding was 
confirmed in cohorts of patients from different Centres. The clinical relevance 
of the response at 1 week strengthens the importance of our cytotoxic assay 
described in Chapter 3, since this biomarker is predictive of an early 
response. We anticipate that, once validated in larger cohort of patients, this 
biomarker could be devised to predict patients’ long-term outcome. 
 
Our observation has also other important implications. In current practice, 
response to MSC treatment has been assessed after 28 days338,430, based on 
previous recommendations that 28 days would represent the most reliable 
time point to predict survival of GvHD patients431. However, it is not clear 
whether an early time point can be used to reliably categorize patients at high 
risk of treatment failure or who may benefit from starting alternative 
therapeutic options. The importance of this problem has been already the 
focus of intense debate in GvHD patients (although not referred specifically 
to MSC treatment) and several studies have identified earlier endpoints as 
predictors of later outcomes432,433. Our data demonstrate that clinical 
responses at 1 week after MSC infusion can be considered an early predictor 
of treatment failure. An early assessment has therefore the advantage to 
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provide crucial information to promptly offer alternative approaches both in 
clinical practice and in the context of clinical trials. 
 
This approach might underestimate the rate and magnitude of clinical 
responses. In fact, the rate of CR in our cohorts is very low compared to other 
studies329,342. In our study, we could not document whether our responding 
patients eventually achieved CR at later time points, because we were unable 
to retrieve consistent data after day 7. However, the obtainment of any kind 
of response, either partial or complete, was sufficient to affect OS. This is 
consistent with previous studies in patients who, like ours, were refractory to 
several lines of treatment331,337–339,345,430. 
 
We also found that MSC dose, age of MSC-recipients and GvHD organ 
involvement are all factors affecting the response to MSCs. Because of the 
retrospective nature of the study, the dose range of MSCs was large thereby 
allowing us to identify a significant association between higher doses and a 
positive response. This observation is in contrast with other reports329,330,338, 
but the discrepancy could be ascribed to the fact that in those studies the 
dose ranges were too narrow and the number of patients too small to identify 
any correlation between response and dose. Indeed, our data have been 
confirmed by a recent multicenter prospective study, in which patients who 
received doses of 3-4x106/Kg body weight had better responses and longer 




Our study confirms that patient age and the affected organ significantly affect 
responses to MSCs329,335,341,342,430. In contrast, we could not find any 
association between GvHD grade242,341,430, time from GvHD330 or from 
HSCT430 to MSC treatment and response to MSCs. 
 
In summary, our data strengthen the role of the MSC recipient rather than the 
one of MSC donor or source in predicting clinical responses. This observation 
is supported by the findings of other groups297,327,329,330,338, whereby when 
MSCs from the same donor were used to treat several patients, only a 
proportion of them achieved a response. Such a perspective suggests that 
the variability in MSC manufacturing bears a limited impact371. Overall, these 
findings strengthen the experimental data and the vision described in the 
previous Chapters and provide an innovative angle to improve the design of 
future clinical studies for the treatment of GvHD with MSCs
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6 Conclusions and Future directions 
 
MSCs have received centre stage attention because they exhibit potent 
immunosuppressive and anti-inflammatory activities1,33 that have been 
extensively tested in several medical conditions, ranging from autoimmune 
diseases to the immunological complications of clinical transplantation, 
including GvHD. The extensive clinical use has been undeterred by the fact 
that the mechanisms underlying MSC therapeutic activity remain largely 
unresolved. The design of studies to convincingly assess MSC efficacy has 
been undermined by a few unresolved challenges. The first is the lack of early 
predictors of clinical responses, which severely delays the assessment of 
treatment success or failure. The second is that, only a proportion of patients 
responds to MSC infusions, and this response cannot be predicted. The third 
is that MSCs are not required to engraft to be efficacious. 
 
In our study we addressed these questions, and we demonstrated that 
assessment of the response at 1 week is a reliable predictor of treatment 
failure. Furthermore, as summarized in Figure 6.1, by tracking the fate of 
MSCs after infusion, we demonstrated that MSCs are induced to undergo 
apoptosis by the cytotoxic cells of the recipient and this is instrumental for 
MSC therapeutic activity. Indeed, immunosuppression could be elicited only 




These findings represent a paradigm shift in MSC therapeutics because we 
resolved the paradox of the presence of clinical activity in the absence of any 
engraftment. A further impact of our discovery is that the principle 
underpinning this mechanism could be used as a biomarker to predict clinical 
responses to MSCs and therefore stratify GvHD patients for MSC treatment.
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Figure 6.1. MSC immunomodulation depends on the interaction with the host. Schematic representation of MSC mediated 
immunosuppression after infusion. 1: After infusion, MSCs interact with the cytotoxic granules produced by CD8+ cells and NK cells 
of MSC recipient. 2: MSCs are induced to undergo apoptosis. 3: apoptotic MSCs are cleared from the circulation by the Mononuclear 
Phagocyte System (MPS). After efferocytosis, phagocytic cells of MSC recipient are induced to produce IDO which is the final mediator 
of MSC immunosuppression. 
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The role played by the cytotoxic cells and the production of IDO by host 
phagocytes, along with MSC-recipient age and GvHD organ involvement, 
strengthen patient’s criticality for the achievement of a clinical response to 
MSCs. We therefore believe that the next generation of clinical trials should 
shift from choosing the best MSC population to choosing the patients most 
likely to respond. However, the cytotoxic assay that we propose to stratify 
patients for treatment can also be devised as a tool to standardize MSC 
manufacturing, and provide a new release criterion for regulatory 
authorities434 and fulfilment of industrial demands435 because it can support 
harmonization across the MSC products as an immunosuppressive agents. 
 
The intriguing possibility that ApoMSCs may be effective in patients otherwise 
refractory to “conventional” “alive” MSCs paves the way to new avenues in 
the clinical manufacturing of MSCs. 
 
Our data also open new important questions which yet remain to be evaluated 
in future studies. Whether and how the cytotoxic activity against MSCs is 
linked to recipient age and GvHD organ involvement, factors associated to 
response329,335,341,342,430, need further investigations in larger studies. An 
important issue is whether children bear a stronger cytotoxic signature than 
older patients. Conversely, in the case the cytotoxicity is the same, the impact 
of the age on response can be mainly dependent on the different therapeutic 
approaches between the two groups, considering that children are usually 
treated early after steroid failure. This consideration raises another important 
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question about the possible detrimental effects of concomitant or previous 
therapies on the capacity of patients to induce MSC apoptosis or tolerogenic 
phagocytic cells after the uptake of the apoptotic bodies. 
 
Another important question is how MSC apoptosis can be placed in the 
armamentarium of MSC immunosuppressive properties. It is likely that the 
signaling pathways associated with caspase activation and apoptosis prompt 
MSCs to directly produce immunosuppressive molecules, or interactions with 
other cells that may strengthen the final immunosuppressive effect and 
promote a long-term tolerogenic activity, as suggested by clinical data. 
Indeed. we have learned that it is the early evidence of a clinical response to 
be sufficient to predict patients’ overall survival. This finding strongly suggests 
that MSCs are instrumental at re-educating the recipient immune system 
rather than simply suppressing an exuberant immune response. 
 
This dissertation provides an explanation of some of the discrepancies that 
have undermined our understanding of MSC immunobiology. However, we 
are only scratching the surface of the challenge in our attempt to improve the 
use of MSCs in GvHD and other inflammatory diseases. New questions need 
to be addressed and new paths identified to pave the way. 
 
This study has not addressed the question why ApoMSCs exerted an 
immunosuppressive activity which seems to be less potent than that of MSCs 
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when administered alive. Since we have not studied whether a cytokine-
dependent licensing coexists with the generation of apoptotic MSCs, we 
cannot exclude that, before undergoing apoptosis, MSCs directly inhibit 
inflammatory reactions through the conventional pathways. 
 
It is possible that before dying, MSCs are still capable to generate an 
immunosuppressive niche by means of soluble factors or interaction with 
other cells. Thus, it can be speculated that, to generate their maximal 
therapeutic potential, MSCs need first to home to the site of injury or 
inflammation, and only when there they need to be induced to undergo 
apoptosis. A very attractive hypothesis could be to genetically engineer MSCs 
with the ability to self-activate apoptosis upon activation of an inducible 
suicide gene, independently of the recipient capacity to kill MSCs. This would 
maximise MSC therapeutic activity in non-responsive patients by delivering 
immunosuppression “on demand” when MSCs home to the target organs, 
whereby they can exert immunosuppression by both the conventional and the 
apoptotic pathways. 
 
A follow-on question regards the extent and the durability of the tolerogenic 
environment created by apoptotic MSCs. The restricted location of MSC 
apoptosis does not seem to reconcile with the systemic effects on 
inflammation. However, the tolerogenic phagocytes generated as a 
consequence of efferocytosis of apoptotic MSCs are in principle conveyors of 
infectious tolerance, since it has been demonstrated that IDO production by 
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macrophages engulfing apoptotic cells initiate the induction of an 
immunosuppressive phenotype of neighboring cells374,375,436. 
 
“The beginning of knowledge is the discovery of something we do not 
understand” (Frank Herbert). The concept of the need for MSCs to be killed 
after administration may be a beginning of a new fascinating era of this potent, 
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